(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 0 436 398 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
31.01.1996 Bulletin 1996/05

(51) Int Cl.[6]: **C07D 213/80**

(21) Application number: **90314412.9**

(22) Date of filing: **28.12.1990**

(54) Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity

Mit einer heteroaromatischen Gruppe und einer Phenylgruppe disubstituierte Acetylene mit retinoidähnlicher Aktivität

Acétylènes substitués par un groupe hétéroaromatique et un groupe phényle ayant une activité semblable aux rétinoides

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: **29.12.1989 US 458963**

(43) Date of publication of application:
10.07.1991 Bulletin 1991/28

(73) Proprietor: **ALLERGAN, INC.**
Irvine, California 92713-9534 (US)

(72) Inventor: **Chandraratna, Roshantha A.S.**
El Toro, California 92630 (US)

(74) Representative: **Hutchins, Michael Richard et al**
Horley, Surrey RH6 7BN (GB)

(56) References cited:
EP-A- 0 284 261 **EP-A- 0 284 288**

- **CHEMISTRY LETTERS, no. 5, 1989, page 773-776; N. NISHIWAKI et al.: "A novel ethynylation of pyridines by reissert-henze type reaction"**
- **JOURNAL OF MEDICINAL CHEMISTRY, vol. 7, 1964, pages 150-154; J. LEHRFELD et al. : "Synthesis of 6-substituted nicotinic acid derivatives as analogs of ergotalkaloids"**

EP 0 436 398 B1

Printed by Jouve, 75001 PARIS (FR)

Description

Background

This invention relates to novel compounds having retinoid like activity. More specifically, the invention relates to compounds having a substituted heteroaromatic portion and a substituted phenyl portion both of which are linked to an ethynyl moiety.

Related Art

Nishikawa et al, Chemistry Letters, pp. 773-776, 1989 describe synthetic methods for preparing various ethynylated pyridines. However, no therapeutic utility is disclosed or suggested for the compounds.

Lehrfeld et al, J. Med Chem., pp. 150-154, 1964 disclose phenethynyl nicotinates as synthetic intermediates but do not disclose any therapeutic utilities for the intermediates.

EP-A-284288 discloses a class of compounds, which have retinoid-like activity, the compounds having an arylethynyl moiety attached to a chromanyl, thiochromanyl or tetrahydroquinolinyl group.

EP-A-284261 discloses a class of arylethynyl-tetralin compounds having retinoid-like activity.

Carboxylic acid derivatives useful for inhibiting the degeneration of cartilage of the general formula 4-(2-(4,4-dimethyl-6-X)-2-methylvinyl)benzoic acid where X is tetrahydroquinolinyl, chromanyl or thiochromanyl are disclosed in European Patent Application 0133795 published January 9, 1985 See also European Patent Application 176034A published April 2, 1986 where tetrahydronaphthalene compounds having an ethynylbenzoic acid group are disclosed, and United States Patent No. 4,739,098 where three olefinic units from the acid-containing moiety of retinoic acid are replaced by an ethynyl-phenyl functionality.

Summary of the Invention

This invention provides compounds of Formula 1



Formula 1

wherein

R_1-R_3 independently are hydrogen, C_{1-8} alkyl, cycloalkyl or lower alkenyl, A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, lower alkenyl, SR* or OR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl,
Y is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl or oxazolyl; E is lower alkenyl, lower alkynyl, lower cycloalkyl, C_{1-8} branched chain alkyl, or $(CH_2)_n$ where n is 0-6; and Z is H, OH, OR^1, $OCOR^1$, -COOH or a pharmaceutically acceptable salt, ester or amide thereof, $-CH_2OH$ or an ether or ester derivative, or -CHO or an acetal derivative, or -COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, for use in medicine, for example in treating skin disorders in a mammal.

In a second aspect, this invention relates to the use of the compounds of Formula 1 for the manufacture of a medicament for treating skin disorders, and in particular dermatoses, such as acne, Darier's disease, psoriasis, icthyosis, eczema, atopic dermatitis and epithelial cancers. These compounds are also useful in the treatment of arthritic diseases and other immunological disorders (e g. lupus erythematosus), in promoting wound healing, in treating dry eye syndrome and in delaying sun damage or reversing the effects of sun damage to skin. The compounds are further useful for treating disorders of gut epithelial differentiation, such as ileitis colitis and Krohn's disease.

This invention also relates to a pharmaceutical formulation comprising a compound of Formula 1 in admixture with

a pharmaceutically acceptable excipient.

In a further aspect, the invention provides novel compounds, said novel compounds having the general formula (1) as hereinbefore defined but excluding compounds wherein when R_1, R_2, R_3, A and B are all hydrogen, Y is pyridyl.

In another aspect, this invention relates to the process for making a compound of Formula 1 which process comprises reacting a compound of Formula 2 with a compound of Formula 3 in the presence of cuprous iodide and $Pd(PQ_3)_2Cl_2$ (Q is phenyl) or a similar complex



Formula 2



Formula 3

where R_1-R_3 are the same as described above, **X** is a halogen, preferably iodine; **A, B, E,** and **Y** are the same as defined above; and Z is H, or an ester or an amide, or a protected or unprotected acid, alcohol, aldehyde or ketone, giving the corresponding compound of **Formula 1**; or to the process of making a compound of **Formula 1** which consists of reacting a zinc salt of a compound shown in **Formula 2** with a compound of **Formula 3** in the presence of $Pd(PQ_3)_4$ (Q is phenyl) or a similar complex.

In still another aspect, the present invention also relates to preparation of compounds of **Formula 1** by conversion of compounds having the structure of **Formula 4**.



Formula 4

In **Formula 4** the symbols **A, B,** R_1 - R_3, **Y** and **E** are defined as above in connection with **Formula 1**, and **Z'** symbolizes such precursors of the group **Z** which can be readily converted by reactions well known to organic chemists, into the desired **Z** group. Thus, the present invention also relates to the above-noted processes involvings steps such as:

converting an acid of **Formula 4** to a salt; or
forming an acid addition salt;
converting an acid of **Formula 4** to an ester; or
converting an acid or ester of **Formula 4** to an amide; or
reducing an acid or ester of **Formula 4** to an alcohol or aldehyde; or
converting an alcohol of **Formula 4** to an ether or ester; or
oxidizing an alcohol of **Formula 4** to an aldehyde; or
converting an aldehyde of **Formula 4** to an acetal; or
converting a ketone of **Formula 4** to a ketal,
extending by homologation the length of the alkyl chain of a compound of **Formula 4**.

General Embodiments

Definitions

The term "ester" as used here refers to and covers any compound falling within the definition of that term as classically used in organic chemistry. Where Z (of **Formula 1**) is -COOH, this term covers the products derived from treatment of this function with alcohols. Where the ester is derived from compounds where Z is $-CH_2OH$, this term covers compounds of the formula $-CH_2OOCR'$ where R' is any substituted or unsubstituted aliphatic, aromatic or aliphatic-aromatic group.

Preferred ethers and esters are derived from the saturated aliphatic alcohols or acids of ten or fewer carbon atoms or the cyclic or saturated aliphatic cyclic alcohols and acids of 5 to 10 carbon atoms. Particularly preferred ethers and esters are those derived from lower alkyl acids or alcohols Here, and where ever else used, lower alkyl means having 1-8 carbon atoms and includes straight and branched chained groups as well. Also preferred are the phenyl or lower alkylphenyl ethers and esters.

Amide has the meaning classically accorded that term in organic chemistry. In this instance it includes the unsubstituted amides and all aliphatic and aromatic mono-and di-substituted amides. Preferred amides are the mono- and di-substituted amides derived from the saturated aliphatic radicals of ten or fewer carbon atoms or the cyclic or saturated aliphatic-cyclic radicals of 5 to 10 carbon atoms. Particularly preferred amides are those derived from lower alkyl amines Also preferred are mono- and di-substituted amides derived from the phenyl or lower alkylphenyl amines. Unsubstituted amides are also preferred.

Acetals and ketals include the radicals of the formula -CK where K is $(-OR')_2$. Here, R' is lower alkyl. Also, K may be -OR'O- where R' is lower alkyl of 2-5 carbon atoms, straight chain or branched.

A pharmaceutically acceptable salt may be prepared for any compound of this invention having a functionality capable of forming such salt, for example an acid or an amine functionality. A pharmaceutically acceptable salt may be any salt which retains the activity of the parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered.

Such a salt may be derived from any organic or inorganic acid or base. The salt may be a mono or polyvalent ion. Of particular interest where the acid function is concerned are the inorganic ions, sodium, potassium, calcium, and magnesium. Organic amine salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and similar molecules. Where there is a nitrogen sufficiently basic as to be capable of forming acid addition salts, such may be formed with any inorganic or organic acids or alkylating agent such as methyl iodide. Preferred salts are those formed with inorganic acids such as hydrochloric acid, sulfaric acid or phosphoric acid. Any of a number of simple organic acids such as mono-, di- or tri-acid may also be used.

The preferred compounds of this invention are those where the ethynyl group and the **Z** group are attached to the 2 and 5 positions respectively of a pyridine ring (the 6 and 3 positions in the nicotinic acid nomenclature being equivalent to the 2/5 designation in the pyridine nomenclature) or the 5 and 2 positions respectively of a thiophene group respectively; **n** is 0; and **Z** is -COOH, an alkali metal salt or organic amine salt, or a lower alkyl ester, or $-CH_2OH$ and the lower alkyl esters and ethers thereof, or -CHO and acetal derivaives thereof. The more preferred compounds shown in **Formula 5** are:

ethyl 6-(3-tert butylphenyl)-ethynyl nicotinate (**Compound 1**, A = $(CH_3)_3C$, B = H, R* = CH_2-CH_3);
6-(3-tert butylphenyl)-ethynyl nicotinic acid (**Compound 2**, A = $(CH_3)_3C$, B = H, R* = H;
ethyl 6-(4-tert butylphenyl)-ethynyl nicotinate (**Compound 3**, A = H, B = $(CH_3)_3C$, R* = CH_2-CH_3);
6-(4-tert butylphenyl)-ethynyl nicotinic acid (**Compound 4**, A = H, B = $(CH_3)_3C$, R* = H);
ethyl 6-[4-(4-methylpentyl)phenyl-ethynyl] nicotinate (**Compound 5**, A = H, B = $(CH_3)_2CH$-$(CH_2)_3$, R* = CH_2-CH_3), and
6-[4-(4-methylpentyl)phenyl-ethynyl] nicotinic acid (**Compound 6**, A = H, B = $(CH_3)_2CH$-$(CH_2)_3$, R* = H.
Ethyl 6-[4-(1,1,4-trimethylpentyl)phenylethynyl] nicotinate. (**Compound 6a**. A = H, B = $(CH_3)_2CH(CH_2)_2C(CH_3)_2$, R* = CH_2 CH_3
6-[4-(1,1,4-trimethylpentyl)phenylethynyl nicotinic acid (**Compound 6b**, A = H, B = $(CH_3)_2CH(CH_2)_2C(CH_3)_2$, R* = H
ethyl 6-(3-thio-tert-butoxyphenyl)-ethynyl nicotinate (**Compound 7**, A = $(CH_3)_3CS$, B = H, R* = CH_2-CH_3);
6-(3-thio-tert-butoxyphenyl)-ethynyl nicotinic acid (**Compound 8**, A = $(CH_3)_3CS$, B = H, R* = H);
ethyl 6-(4-thio-tert-butoxyphenyl)-ethynyl nicotinate (**Compound 9**, A = H, B = $(CH_3)_3CS$, R* = CH_2-CH_3);
6-(4-thio-tert-butoxyphenyl)-ethynyl nicotinic acid (**Compound 10**, A = H, B = $(CH_3)_3CS$, R* = H);
ethyl 6-[4-(3-methyl-thio-2-butenoxyphenyl)]-ethynyl nicotinate (**Compound 11**, A = H, B = $(CH_3)_2C$=CH-CH_2-S-, R* = CH_2-CH_3);

6-[4-(3-methyl-thio-2-butenoxyphenyl)]-ethynyl nicotinic acid (**Compound 12**, A = H, B = $(CH_3)_2C=CH-CH_2-S-$, R* = H;



Formula 5

The compounds of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and similar considerations.

In the treatment of dermatoses, it will generally be preferred to administer the drug topically, though in certain cases such as treatment of severe cystic acne, oral administration may also be used. Any common topical formulation such as a solution, suspension, gel, ointment, or salve and the like may be used. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pennsylvania. For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form.

If the drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like, or as a syrup or elixir for oral administration. For intravenous or intraperitoneal administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as an extended release formulation for deposit under the skin or intermuscular injection.

Other medicaments can be added to such topical formulation for such secondary purposes as treating skin dryness, providing protection against light, other medications for treating dermatoses, preventing infection, reducing irritation, inflammation and the like.

Treatment of dermatoses or any other indications known or discovered to be susceptible to treatment by retinoic acid-like compounds will be effected by administration of the therapeutically effective dose of one or more compounds of the instant invention. A therapeutic concentration will be that concentration which effects reduction of the particular condition, or retards its expansion. In certain instances, the drug potentially could be used in a prophylactic manner to prevent onset of a particular condition. A given therapeutic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, a given therapeutic concentration will be best determined at the time and place through routine experimentation. However, it is anticipated that in the treatment of, for example, acne, or other such dermatoses, that a formulation containing between 0.001 and 5 percent by weight, preferably about 0 01 to 1% will usually constitute a therapeutically effective concentration. If administered systemically, an amount between 0.01 and 100 mg per kg body weight per day, but preferably about 0.1 to 10 mg/kg, will effect a therapeutic result in most instances.

The retinoic acid like activity of these compounds was confirmed through the classic measure of retinoic acid activity involving the effects of retinoic acid on ornithine decarboxylase. The original work on the correlation between retionic acid and decrease in cell proliferation was done by Verma & Boutwell, Cancer Research, 1977, 37, 2196-2201. That reference discloses that ornithine decarboxylase (ODC) activity increased precedent to polyamine biosynthesis. It has been established elsewhere that increases in polyamine synthesis can be correlated or associated with cellular proliferation Thus, if ODC activity could be inhibited, cell hyperproliferation could be modulated. Although all causes for ODC activity increase are unknown, it is known that 12-0-tetradecanoyl-phorbol-13-acetate (TPA) induces ODC activity. Retinoic acid inhibits this induction of ODC activity by TPA. The compounds of this invention also inhibit TPA induction of ODC as demonstrated by an assay essentially following the procedure set out in Cancer Res., 35: 1662-1670, 1975.

By way of example of retinoic acid-like activity it is noted that in the assay conducted essentially in accordance with the method of Verma & Boutwell, ibid, the following examples of the preferred compounds of the present invention

(Compounds 1, 3, 5, 6a, 6b, 7, 9 and 11) attained an 80% inhibition of TPA induced ODC activity at the following concentrations (IC_{80}):

Compound	IC_{80} conc (nmols)
1	19.2
3	11.5
5	-300
6a	95
6b	47
7	27.6
9	36.2
11	33.9

Specific Embodiments

The compounds of this invention can be made by a number of different synthetic chemical pathways. To illustrate this invention, there is here outlined a series of steps which have been proven to provide the compounds of **Formula 1** when such synthesis is followed in fact and in spirit. The synthetic chemist will readily appreciate that the conditions set out here are specific embodiments which can be generalized to any and all of the compounds represented by **Formula 1**. Furthermore, the synthetic chemist will readily appreciate that the herein described synthetic steps may be varied and or adjusted by those skilled in the art without departing from the scope and spirit of the invention.

Referring now specifically to **Reaction Scheme 1**, the compounds of the invention can be synthesized by coupling of a suitable substituted phenylethyne compound (shown and defined in connection with **Formula 2**) with a suitable heterocyclic compound (shown and defined in connection with **Formula 3**) which has a leaving group (**X** in **Formula 3**). In other words, the heteroaryl substituent is coupled to the substituted phenylethyne compound (**Formula 2**) by reacting the latter with a halogen substituted heteroaromatic compound (**Formula 3**) in which the heteroaramatic nucleus (**Y**) either has the desired substituent E-Z or wherein the actual substituent E-Z' can be readily converted to the desired substituent by means of organic reactions well known in the art



REACTION SCHEME 1

Coupling of the substituted phenylethyne compound (**Formula 2**) with the reagent X-Y-E-Z (**Formula 3**) or with the

reagent X-Y-E-Z' (where Z' is defined as above in connection with **Formula 4**) is affected directly in the presence of cuprous iodide, a suitable catalyst, typically of the formula $Pd(PQ_3)_2Cl_2$ and an acid acceptor, such as triethylamine, by heating in a sealed tube under an inert gas (argon) atmosphere.

The resulting disubstituted acetylene compounds may be the target compound made in accordance with the invention (**Formula 1**), or maybe compounds described by **Formula 4** which can be readily converted into the target compounds by such steps as salt formation, esterification, deesterification, homologation, amide formation and the like These steps are further discussed below.

The disubstituted acetylene compounds of the invention (**Formula 1**) may also be obtained by first converting the substituted phenylethyne compounds of **Formula 2** into the corresponding metal salts, such as a zinc salt (**Compound 13**) and thereafter coupling the salt **13** with the reagent X-Y-E-Z (**Formula 3**) or with the reagent X-Y-E-Z' (Z' defined as above) in the presence of a catalyst having the formula $Pd(PQ_3)_4$ (Q is phenyl), or similar complex.

Derivatization of the compounds of **Formula 1** (or of compounds of **Formula 4**) is indicated in **Reaction Scheme 1** as conversion to "Homologs and Derivatives" (**Compounds 14**).

More specifically with respect to either derivatization or deblocking of protected functionalities in compounds corresponding to **Formula 1** or **Formula 4**, or with respect to the preparation of heteroaromatic compounds of the formula X-Y-E-Z or of the formula X-Y-E-Z' (that is intermediates which after coupling either directly yield the compounds of the invention, or yield the compounds of **Formula 4**) the following is noted.

Where a protected heteroaromatic compound is needed to couple with the compounds of **Formula 2** such may be prepared from their corresponding acids, alcohols, ketones or aldehydes. These starting materials, the protected acids, alcohols, aldehydes or ketones, are all available from chemical manufacturers or can be prepared by published methods. Carboxylic acids are typically esterified by refluxing the acid in a solution of the appropriate alcohol in the presence of an acid catalyst such as hydrogen chloride or thionyl chloride. Alternatively, the carboxylic acid can be condensed with the appropriate alcohol in the presence of dicyclohexylcarbodiimide and dimethylaminopyridine. The ester is recovered and purified by conventional means. Acetals and ketals are readily made by the method described in March, "Advanced Organic Chemistry," 2nd Edition, McGraw-Hill Book Company, p 810). Alcohols, aldehydes and ketones all may be protected by forming respectively, ethers and esters, acetals or ketals by known methods such as those described in McOmie, Plenum Publishing Press, 1973 and Protecting Groups, Ed. Greene, John Wiley & Sons, 1981.

To increase the value of **n** before effecting a coupling reaction, where such compounds are not available from a commercial source, the heteroaromatics where **Z** is -COOH are subjected to homologation by successive treatment under Arndt-Eistert conditions or other homologation procedures Alternatively, heteroaromatics where **Z** is different from COOH, may also be homologated by appropriate procedures. The homologated acids can then be esterified by the general procedure outlined in the preceding paragraph.

An alternative means for making compounds where **n** is 0 - 6 is to subject the compounds of **Formula 1**, where **Z** is an acid or other function, to homologation, using the Arndt-Eistert method referred to above, or other homologation procedures.

The acids and salts derived from **Formula 1** are readily obtainable from the corresponding esters. Basic saponification with an alkali metal base will provide the acid. For example, an ester of **Formula 1** may be dissolved in a polar solvent such as an alkanol, preferably under an inert atmosphere at room temperature, with about a three molar excess of base, for example, potassium hydroxide. The solution is stirred for an extended period of time, between 15 and 20 hours, cooled, acidified and the hydrolysate recovered by conventional means.

The amide may be formed by any appropriate amidation means known in the art from the corresponding esters or carboxylic acids. One way to prepare such compounds is to convert an acid to an acid chloride and then treat that compound with ammonium hydroxide or an appropriate amine. For example, the acid is treated with an alcoholic base solution such as ethanolic XOH (in approximately a 10% molar excess) at room temperature for about 30 minutes. The solvent is removed and the residue taken up in an organic solvent such as diethyl ether, treated with a dialkyl formamide and then a 10-fold excess of oxalyl chloride. This is all effected at a moderately reduced temperature between about -10 degrees and +10 degrees C. The last mentioned solution is then stirred at the reduced temperature for 1-4 hours, preferably 2 hours. Solvent removal provides a residue which is taken up in an inert inorganic solvent such as benzene, cooled to about 0 degrees C and treated with concentrated ammonium hydroxide. The resulting mixture is stirred at a reduced temperature for 1 - 4 hours. The product is recovered by conventional means.

Alcohols are made by converting the corresponding acids to the acid chloride with thionyl chloride or other means (J. March, "Advanced Organic Chemistry", 2nd Edition, McGraw-Hill Book Company), then reducing the acid chloride with sodium borohydride (March, Ibid, pg. 1124), which gives the corresponding alcohols Alternatively, esters may be reduced with lithium aluminum hydride at reduced temperatures. Alkylating these alcohols with appropriate alkylhalides under Williamson reaction conditions (March, Ibid, pg. 357) gives the corresponding ethers. These alcohols can be converted to esters by reacting them with appropriate acids in the presence of acid catalysts or dicyclohexylcarbodiimide and dimethylaminopyridine.

Aldehydes can be prepared from the corresponding primary alcohols using mild oxidizing agents such as pyridinium

dichromate in methylene chloride (Corey, E. J., Schmidt, G., Tet. Lett., 399, 1979), or dimethyl sulfoxide/oxalyl chloride in methylene chloride (Omura, K., Swern, D., Tetrahedron. 1978, 34, 1651).

Ketones can be prepared from an appropriate aldehyde by treating the aldehyde with an alkyl Grignard reagent or similar reagent followed by oxidation

Acetals or ketals can be prepared from the corresponding aldehyde or ketone by the method described in March, Ibid, p 810.

Compounds where **Z** is H can be prepared from the corresponding halo-heterocyclic entity, preferably where the halogen is iodine.

The intermediate substituted phenylethynes (compounds of **Formula 2**) can be prepared from substituted phenyl compounds in accordance with the reactions described below.

Alkyl, cycloalkyl or alkenyl substituted phenylethynes (compounds shown in **Formula 2** where R_1 - R_3 as well as **A** and **B** independently are hydrogen, lower alkyl, cycloalkyl, or lower alkenyl) can be synthesized in accordance with **Reaction Scheme 2**, starting from a halogen (preferably bromo or iodo) substituted phenyl compound (**Compound 15**). **Compound 15** is reacted with trimethylsilylacetylene **Compound 16** in the presence of cuprous iodide and a suitable catalyst, typically having the formula $Pd(PQ_3)_2Cl_2$ (Q is phenyl). The reaction is typically conducted in the presence of bis(triphenylphosphine) palladium (II) chloride catalyst, an acid acceptor, (such as triethylamine) under an inert gas (argon) atmosphere, by heating in a sealed tube. The resulting alkyl or alkenyl substituted trimethylsilylethynylbenzene is shown as **Compound 17** in **Reaction Scheme 2**.



Reaction Scheme 2

As is shown on **Reaction Scheme 2**, the trimethylsilyl moiety is removed from the trimethylsilylethynylbenzene **17** in the next synthetic step, to provide the alkyl or alkenyl substituted ethynylbenzene derivative (**Compound 18**). The latter reaction is conducted under basic conditions, preferably under an inert gas atmosphere.

Reaction Scheme 3 discloses a specific synthetic route to 4-tert-butylphenyl ethyne (**Compound 19**) starting with 4-bromo t-butylbenzene (**Compound 20**) which is either available commercially or is readily synthesized in accordance with known prior art. Thus, 4-bromo t-butylbenzene **20** is heated with trimethylsilylacetylene **16** in the presence of cuprous iodide, bis(triphenylphosphine) palladium (II) chloride catalyst, and triethylamine under an inert gas atmosphere. The resulting trimethylsilyl-(4-tert-butyl)phenylethyne (**Compound 21**) is reacted with aqueous KOH in isopropanol to yield 4-tert-butylphenyl ethyne **19**.



Reaction Scheme 3



Reaction Scheme 4

Reaction Scheme 4 discloses a specific synthetic route to 3-tert-butylphenyl ethyne (**Compound 22**) starting with meta bromobenzoic acid (**Compound 23**), which is treated with trimethylaluminum in hexane to yield 3-tert-butyl bromobenzene (**Compound 24**). 3-Tert-butyl bromobenzene **24** is thereafter converted into the ethyne derivative **22** through the trimethylsilyl ethyne intermediate **25** in steps similar to the steps described in connection with **Reaction Scheme 3.**

Reaction Scheme 5 discloses a specific synthetic route to 4-(4-methylpentyl)-phenylethyne **(Compound 26)**. In accordance with this scheme, bromobenzene **(Compound 27)** is reacted under Friedel Crafts conditions ($AlCl_3$) with the acid chloride **(Compound 28)** prepared in situ from 4-methyl valeric acid, to yield 4-(1-oxo-4-methyl-pentyl) bromobenzene **(Compound 29)**. **Compound 29** is reduced under Wolff-Xishner conditions (KOH, NH_2NH_2) to yield 4-(4-methylpentyl) bromobenzene **(Compound 30)**. The bromobenzene derivative **30** is converted to the ethyne derivative **26** through the intermediate trimethylsilyl ethyne derivative **31** in a manner similar to the conversion described in connection with **Reaction Scheme 3.**



Reaction Scheme 5

Reaction Scheme 6 discloses specific synthetic steps leading to 4-(1,1,4-trimethylpentyl)phenylethyne (**Compound 32**). In this synthetic route 4-(1-oxo-4-methyl-pentyl) bromobenzene (**Compound 29**, obtained as shown in **Reaction scheme 5**) is reacted under a nitrogen atmosphere with trimethylaluminum in hexane to yield 4-(1,1,4-trimethylpentyl)bromobenzene (**Compound 33**). The bromobenzene derivative **33** is converted through the corresponding trimethylsilylethyne derivative **34** into the target intermediate **32** by treatment with trimethylsilyl ethyne and subsequently with KOH in isopropanol, as described above.



Reaction Scheme 6

Specific examples of coupling the above-noted phelylethynes with reagents of the **General Formula 3** are disclosed below under the heading "Specific Examples".

Alkylthio, alkyloxy, cycloalkylthio, cycloalkyloxy, alkenylthio, and alkenyloxy substituted phenylethynes which may or may not be additionally substituted with alkyl, cycloalkyl or alkenyl groups, in other words, compounds shown in **Formula 2** where R_1 - R3 independently are hydrogen, lower alkyl, cycloalkyl, or lower alkenyl and where at least one of **A** and **B** is alkylthio, alkyloxy, cycloalkylthio, cycloalkyloxy, alkenylthio, or alkenyloxy, can be synthesized in accordance with the steps outlined in **Reaction Scheme 7**.

Thus, in accordance with **Reaction Scheme 7** a halogen substituted phenol, preferably an iodopheol or a bromophenol, or a corresponding thiophenol **(Compound 35)** which may or may not be additionally substituted with an alkyl, alkenyl or cycloalkyl group (in **Compound 35 X'** is halogen, **Y'** is sulphur or oxygen and R_1 - R_3 are defined as in connection with **Formula 1**) is alkylated with a reagent R*-X" where **X"** is a leaving group such as a halogen, and **R*** is defined as in connection with **Formula 1**. Alternatively, the **R*** group can also be formed by reacting the halogen substituted thiophenol or phenol **(Compound 35)** with an appropriate alkene. The resulting alkoxy, thio-alkoxy, alkenoxy or thio-alkenoxy halobenzene **(Compound 36)** is reacted with trimethylsilylacetylene **(Compound 16)** in the presence of cuprous iodide and a suitable catalyst, such as $Pd(PQ_3)_2Cl_2$, where Q is phenyl. As is noted in connection with the analogous reaction disclosed in **Reaction Scheme 2**, the reaction is typically conducted in the presence of bis(triphenylphosphine) palladium (II) chloride catalyst, and an acid acceptor, such as triethylamine, under an inert gas (argon) atmosphere. The resulting alkoxy, thio-alkoxy, alkenyloxy or thio-alkenyloxy trimethylsilylethynylbenzene derrivatives are shown as **Compound 37** in **Reaction Scheme 7.**



Reaction Scheme 7

The trimethylsilyl moiety is removed from the trimethylsilylethynylbenzene **37** in the next synthetic step, to provide the alkoxy, thio-alkoxy, alkenoxy or thio-alkenoxy substituted ethynylbenzene derivative **(Compound 38).**



Reaction Scheme 8

Reaction Scheme 8 discloses a specific series of synthetic steps which lead to 4-thio-tert-butoxyphenyl ethyne **(Compound 39).** Thus, 4-bromo-thiophenol **(Compound 40)** is reacted with isobutylene gas to yield 4-bromophenyl-tert-butyl-sulfide **(Compound 41).** Compound 41 is thereafter reacted under the conditions described above, with trimethylsilylacetylene **(Compound 16)** and the resulting trimethylsilyl phenylethyne derivative **42** is thereafter hydrolyzed to yield **Compound 39.** The corresponding 3-thiotert-butoxyphenyl ethyne **(Compound 43)** can be synthesized from 3-bromo-thiophenol under substantially similar conditions.



Reaction Scheme 9

Reaction Scheme 9 discloses synthetic steps which lead to 4-(3-methyl-thio-2-butenoxy)phenyl ethyne **(Compound 44).** 4-Bromo-thiophenol **(Compound 40)** is heated with 4-bromo-2-methyl-2-butene **(Compound 45)** in a suitable solvent (such as acetone) in the presence of strong base (NaOH) to yield 4-bromophenyl-3-methyl-2-butenyl-sulfide **(Compound 46). Compound 46** is converted to the ethyne derivative **44** through the trimethylsilyl ethyne compound **47** by the reactions which are described above.



Reaction Scheme 10

Reaction Scheme 10 illustrates specific synthetic steps which can be utilized to obtain 4-(3-methyl-thiobutoxy) -phenyl ethyne **(Compound 48).** In this synthetic procedure 4-bromo-thiophenol **(Compound 40)** is heated with 1-bromo-3-methyl-2-butane **(Compond 49)** in a suitable solvent in the presence of strong base (refluxing acetone and NaOH) to yield 4-bromophenyl-3-methylbutyl-sulfide **(Compound 50). Compound 50** is transformed to the desired ethyne derivative **48** through the intermediate trimethylsilylethyne **51**.



FORMULA 2

Reaction Scheme 11

An alternative general route for introducing the ethyne (acetylenic) function into a phenyl or substituted phenyl derivative so as to obtain the intermediates of **Formula 2,** is disclosed in **Reaction Scheme 11.** In accordance with this general procedure, a suitably substituted benzene derivative **(Compound 52)** is acetylated under Friedel Crafts conditions to provide the acetophenone derivative **53**. The acetylation is preferably conducted in the presence of $AlCl_3$ and in nitromethane solvent. The acetylenic (triple) bond is introduced into the molecule by converting the acetyl moiety of the acetophenone derivative **53** to an acetylene moiety. This is accomplished, preferably, by treatment with lithium diisopropylamide (at low temperature, such as - 78 degrees C) which causes enolization of the acetyl group. The intermediate enol compound (not shown in **Reaction Scheme 11**) is esterified by treatment with diethylchlorophosphate (or the like) and is again reacted at reduced temperature (e.g. - 78 degrees C) with two equivalents of lithium diisopropylamide, to form the triple bond (presumably by an elimination reaction) and to yield the compounds of **Formula 2.**

It is noted at this point that the present invention is not intended to be limited or bound by the above-mentioned and other theories of reaction mechanisms. Brief description of the theories of reaction mechanism of the above-noted reaction is given to further enable and facilitate the work of a skilled artisan in the field to modify and adjust the synthetic conditions to fit particular specific intermediates and to make the several compounds of the invention.

The following examples of specific compounds of the invention, and specific examples of the synthetic steps in which the compounds and certain intermediates are made, are set out to illustrate the invention.

Specific Examples

Ethyl 6-chloronicotinate **(Compound 54)**

A mixture of 15.75 g (0.1 mol) 6-chloronicotinic acid, 6.9 g (0.15 mol) ethanol, 22.7 g (0.11 mol) dicyclohexylcarbodiimide and 3.7 g dimethylaminopyridine in 200 ml methylene chloride was heated at reflux for 2 hours. The mixture was allowed to cool, solvent removed in vacuo and residue subjected to flash chromatography to give the title compound as a low-melting white solid. PMR ($CDCl_3$). & 1.44 (3H, t, J-6.2 Hz) 4.44 (2H, q, J-4.4 Hz), 7.44 (1H, d, J-8.1 Hz), 8.27 (1H, dd, J-8.1 Hz, 3 Hz), 9.02 (1H, d, J-3 Hz)

The foregoing procedure may be used to esterify any of the other halo-substituted acids employed in the making of compounds of the invention, such as:

ethyl 2-(2-chloropyrid-5-yl)acetate;
ethyl 5-(2-chloropyrid-5-yl)pentanoate;
ethyl 2-(2-iodofur-5-yl)acetate;
ethyl 5-(2-iodofur-5-yl)pentanoate;

ethyl 2-(2-iodothien-5-yl)acetate;
ethyl 5-(2-iodothien-5-yl)pentanoate;
ethyl 2-(3-chloropyridazin-6-yl)acetate;
ethyl 5-(3-chloropyridazin-6-yl)pentanoate; and the corresponding chloro, or other halo, substituted pyrimidinyl or pyrazinyl analogues of such esters. The just mentioned esters (including ethyl-6-chloronicotinate, **Compound 54**) can serve as the reagents, X-Y-E-Z for coupling with the correspoding ethynyl compounds (such as Compounds **19, 22, 26, 32, 39, 44, and 48,** or their zinc salts) to provide the target compounds of the invention.

3-Tert-butyl bromobenzene **(Compound 24)**

A suspension of 4.02 g (20 mmol) of m-bromobenzoic acid **(Compound 23)** in 10 ml hexane was cooled in an ice-bath under nitrogen and then treated slowly with 40 ml of 2 M (80 mmol) trimethylaluminum in hexane. The hexane was removed by distillation under nitrogen and the apparatus modified for reflux. The reaction mixture was then heated in an oil bath at 140 - 150 degrees C for 3 hours The oil bath was then replaced by an ice-water bath and the reaction mixture was quenched by the slow dropwise addition of water. The mixture was acidified with dilute HCl and mixture heated at reflux until the aluminum salts were dissolved. The reaction mixture was allowed to cool and extracted with 3 X 8 ml ether. The ether extracts were combined, washed with dil. HCl, water and saturated NaCl and then dried ($MgSO_4$). The solvent was removed in-vacuo and the residue distilled to give a mixture of the title compound and 3-(1-methyl-ethenyl) bromobenzene as a colorless oil. A small portion (200 mg) of this mixture was dissolved in 1 ml of methylene chloride and then treated with a solution of 200 mg of m-chloroperbenzoic acid in 4 ml of methylene chloride The mixture was stirred at room temperature for 1 hour and the methylene chloride removed in-vacuo. The residue was dissolved in hexane and filtered through a short silica column and the filtrate concentrated in-vacuo to give pure title compound as a colorless oil. PMR ($CDCl_3$)· & 1.30 (9H, s), 7.25 (1H, m), 7.41 (2H, m), 7.65 (H, t, J - 2.1 Hz)

4-(1-oxo-4-methyl-pentyl) bromobenzene **(Compound 29)**

A mixture of 25 g (.215 mol) of 4-methyl valeric acid and 29 35 g (.247 mol) of thionyl chloride was heated at reflux for 1.5 hour. The excess thionyl chloride was removed under reduced pressure using a cryogenic trap. The residue was taken up with 120 g (.764 mol) of bromobenzene **(Compound 27)** and the mixture was cooled in an ice-bath and then treated with 23 g (.172 mol) of anhydrous aluminum chloride through a powder addition funnel. The mixture was stirred at room temperature for 82 h and then quenched by the addition of 50 ml of an ice/water mixture, followed by 30 ml of conc. HCl. The organic layer was separated and the aqueous layer extracted with 2 X 50 ml of ether. The organic extracts were combined and washed successively with water and saturated NaCl solution and then dried ($MgSO_4$). The solvent was then removed in-vacuo and the residue purified by distillation (- 80 degrees C/.01 mm) to give the title compound as a colorless solid. PMR ($CDCl_3$): & 0.94 (6 H, d, J - 6.0 Hz), 1 53 - 1.68 (3H, m), 2.85 - 2 97 (2H, m)., 7.60 (2H, d, J - 8 4 Hz), 7.83 (2H, d, J - 8.4 Hz).

4-(4-methylpentil) bromobenzene **(Compound 30)**

A mixture of 6.45 g (115 mmol) of potassium hydroxide and 42 ml of triethylene glycol was heated at around 100 degrees C until the potassium hydroxide was dissolved. The mixture was allowed to cool and then treated with 10 g (39mmol) of 4-(1-oxo-4-methylpentyl) bromobenzene **(Compound 29)** followed by 3 g (94 mmol) of hydrazine hydrate. The mixture was slowly brought to reflux and heated at reflux for 1 hour. The apparatus was modified for distillation and the mixture heated until approximately 7 ml of liquid had distilled over and the flask temperature had reached 220 degrees C. The apparatus was again modified for reflux and the mixture was heated at reflux for 5 hours and then stirred at room temperature for 8.5 hours. The mixture was then heated to 100 degrees C and poured into 40 ml of water and the flask rinsed with an additional 25 ml of water. This diluted mixture was acidified to pH-2 with conc. HCl and extracted with ether. The ether extract was washed successively with water and saturated NaCl and then dried ($MgSO_4$). The solvent was removed in vacuo and the residue subjected to kugelrohr distillation (70 degrees C, .05 mm) to give the title compound as a colorless oil. PMR ($CDCl_3$) : & 0.88 (6H, d, J - 6 Hz), 1.12 - 1.26 (2H, m), 1.48 - 1.66 (3H, m), 2.54 (2H, t, J - 7.7 Hz) 7.06 (2H, d, J - 8.3 Hz), 7.39 (2H, d, J - 8.3 Hz)

4-(1,1,4-Trimethyl-pentyl) bromobenzene **(Compound 33)**

To a cooled (ice bath) solution of 5 35 g (20 9 mmol) of 4-(1-oxo-4-methylpentyl) bromobenzene **(Compound 29)** and 200 ml of water in 8 ml of chlorobenzene was added slowly, under nitrogen, 20.9 ml of 2M (41.8 mmol) trimethylaluminum in hexane. The hexane was removed by distillation under nitrogen and the residue heated at reflux for 80 hours. The reaction mixture was then cooled in an ice bath and quenched by the slow addition of water. The mixture was then

treated with 24 ml of 2N HCl and heated until the aluminum salts were dissolved. The mixture was cooled and extracted with 3 X 20 ml of ether. The ether extracts were combined and washed successively with water and saturated NaCl and then dried ($MgSO_4$). The solvent was removed in-vacuo and the residue distilled (90 - 100 degrees C / 0.16 mm) to give a crude product which appeared to be a mixture of the desired title compound, starting bromoketone and some olefinic material This product was then dissolved in 20 ml of methylene chloride, treated with 2 g of m-chloroperbenzoic acid and stirred at room temperature for 12 hours. The solvent was then removed in-vacuo and the residue purified by flash chromatography (silica, hexane) to give the title compound as a colorless oil PMR ($CDCl_3$): & 0.82 (6H, d, J - 6 9 Hz), 0.85 - 0.97 (2H, m), 1.27 (6H, s), 1.32 - 1 49 (1H, m), 1.53 - 1.62 (2H, m), 7.20 (2H, d, J - 8.7 Hz), 7.42 (2H, d, J - 8.7 Hz).

Trimethylsilyl (4-tert-butyl) phenylethyne **(Compound 21)**

A stirred mixture of 3.05 g (14. 31 mmol) of 4-tert-butyl-bromobenzene **(Compound 20)**, 1 41 g (14 39 mmol) of trimethylsilylacetylene **(Compound 16)**, 139 mg (0.13 mmol) of cuprous iodide, 293 mg (0 42 mmol) of bis(triphenyophosphine) palladium (II) chloride and 3 ml of triethylamine was flushed with nitrogen and then heated under nitrogen at 65 - 70 degrees C for 20 hours. The reaction mixture was stirred at room temperature for a further 4 hours and the triethylamine then removed under vacuum. The residue was purified by flash chromatography (silica; hexanes) to give the title compound as a colorless oil. PMR ($CDCl_3$): & 0.26 (9H, s), 1.31 (9H, s), 7.32 (2H, d, J - 8.2 Hz), 7.42 (2H, d, J - 8.2 Hz).

Trimethylsilyl (3-tert-butyl) phenylethyne **(Compound 25)**

Using the same general procedure as described for **Compound 21,** but using 3-tert-butyl-bromobenzene, **(Compound 24)** the title compound was synthesized as a colorless oil. PMR ($CDCl_3$): & 0.36 (9H, s), 1.40 (9H, s), 7 32 (1H, m), 7.37 - 7.47 (2H, m), 7.61 (1H, m).

Trimethylsilyl [4-(4-methylpentyl)] phenylethyne **(Compound 31)**

Using the same general procedure as described for **Compound 21,** but using instead 4-(4-methylpentyl) bromobenzene **(Compound 30),** the title compound was synthesized as a colorless oil. PMR ($CDCl_3$). & 0.32 (9H, s), 0.93 (6H, d, J - 6.6 Hz), 1.18 - 1.29 (2H, m), 1.52 - 1.70 (3H, m), 2.58 (2H, t, J - 7.7 Hz), 7.12 (2H, d, J - 8.1 Hz), 7.43 (2H, d, J - 8.1 Hz).

Trimethylsilyl [4-(1,1,4-trimethylpentyl)] phenylethyne **(Compound 34)**

Using the same general procedure as described for **Compound 21,** but using instead 4-(1,1,4-trimethylpentyl) bromobenzene **(Compound 33),** the title compound was synthesized as a colorless oil. PMR ($CDCl_3$): & 0.26 (9H, s), 0.81 (6H, d, J - 6.6 Hz), 0.85 - 0.97 (2H, m), 1.29 (6H, s), 1.33 - 1.46 (1H, m), 1 54 - 2.65 (2H, m), 7.27 (2H, d, J - 8.1 Hz), 7.42 (2H, d, J- 8.1 Hz).

(4-tert-butyl) phenylethyne **(Compound 19)**

To a stirred solution of 1.44 g (6.23 mmol) of trimethylsilyl (4-tert-butyl) phenylethyne **(Compound 21)** in 5 ml of isopropanol was added 10 ml of 1N aqueous KOH and the mixture then stirred at room temperature for 6.5 hours. The isopropanol was removed under vacuum and the residue extracted with ether. The ether extract was washed with dilute HCl until the washings were acidic. The ether solution was then successively washed with water, saturated NaCl and $NaHCO_3$ solutions and then dried ($MgSO_4$). Solvent was then removed in-vacuo to give the title compound as a colorless oil PMR ($CDCl_3$): & 1.34 (9H, s), 3 05 (1H, s), 7.37 (2H, d, J - 8.2 Hz), 7.46 (2H, d, J - 8.2 Hz).

(3-tert-butyl) phenylethyne **(Compound 22)**

Using the same general procedure as described for **Compound 19)**, but using instead trimethylsilyl (3-tert-butyl) phenylethyne **(Compound 25)** and aqueous KOH in methanol, the title compound was synthesized as a colorless oil. PMR ($CDCl_3$): & 1.29 (9H, s), 3.03 (1H, s), 7.22 (1H, t, J - 7.5 Hz), 7.30 (1H, dt, J - 7.5 Hz, 1.5 Hz), 7.36 (1H, dt, J - 7.5 Hz, 1.5Hz), 7.53 (1H, t, J - 1 5 Hz).

[4-(4-methylpentyl)] phenylethyne **(Compound 26)**

Using the same general procedure as described for **Compound 19),** but using instead trimethylsilyl [4-(4-methylpentyl)] phenylethyne **(Compound 31),** the title compound was synthesized as a colorless oil. PMR ($CDCl_3$): & 0.94

(6H, d, J - 6.6 Hz), 1.20 - 1.32 (2H, m), 1.56 - 1 62 (3H, m), 2.64 (2H, t, J - 7.8 Hz), 3.08 (1H, s), 7.18 (2H, d, J - 8.1 Hz), 7.47 (2H, d, J - 8.1 Hz).

[4-(1,1,4-trimethylpentyl)] phenylethyne **(Compound 32)**

Using the same general procedure as described for **Compound 19,** but using instead trimethylsilyl [4-(1,1,4-trimethylpentyl)] phenylethyne **(Compound 34),** the title compound was synthesized as a colorless oil PMR ($CDCl_3$): & 0.81 (6H, d, J - 6.6 Hz), 0.85 - 0.96 (2H, m), 1.29 (6H, s), 1.32 - 1.48 (1H, m). 1.55 - 1 66 (2H, m) , 3.04 (1H, s), 7.29 (2H, d, J - 8.4 Hz), 7.44 (2H, d, J -8.4 Hz).

Ethyl-6-(4-tert-butylphenylethynyl) nicotinate **(Compound 3)**

A mixture of 477.7 mg (3.02 mmol) of 4-tert-butylphenylethyne **(Compound 19),** 556.5 mg (3.01 mmol) of ethyl-6-chloronicotinate **(Compound 54),** 27.8 mg (0.15 mmol) of cuprous iodide, 58.7 mg (0.08 mmol) of bis(triphenylphosphine palladium (II) chloride and 2 ml of triethylamine was degassed under nitrogen and then stirred under nitrogen at room temperature for 40 hours. The mixture was then heated at 65 degrees C for 12 hours, cooled to room temperature and the excess triethylamine removed under vacuum. The residue was taken up in water and extracted with ether. The solvent was then removed in-vacuo and the residue purified by flash chromatography (silica 5% ethyl acetate in hexane) to give the title compound as a pale brown solid. PMR ($CDCl_3$) : & 1.33 (9H, s), 1.42 (3H, t, J - 7.1 Hz); 4.42 (2H, q, J 7.1 Hz), 7.40 (2H, d, J- 8.4 Hz), 7 53 - 7.61 (3H, m), 8.28 (1H, dd, J - 8.1 Hz, 2.0 Hz), 9.20 (1H, d, J - 2.0 Hz).

Ethyl-6-(3-tert-butylphenylethynyl) nicotinate **(Compound 1)**

Using the same general procedure as described for **Compound 3,** but using instead 3-tert-butylphenylethyne **(Compound 19),** the title compound was synthesized as a white solid. PMR ($CDCl_3$): & 1.34 (9H, s), 1.42 (3H, t, J - 7.2 Hz), 4.43 (2H, q, J - 7.2 Hz), 7.28 - 7.36 (1H, m), 7 40 - 7.46 (2H, m), 7.60 (1H, d, J - 8.1 Hz), 7.67 (1H, s), 8.29 (1H, dd, J - 8.1 Hz, 2.1 Hz), 9 21 (1H, d, J - 2.1 Hz).

Ethyl-6-[4-(4-methylpentyll phenylethynyl] nicotinate **(Compound 5)**

Using the same general procedure as described for **Compound 3**, but using instead 4-(4-methylpentyl) phenylethyne **(Compound 26)** the title compound was synthesized as a yellow solid. PMR ($CDCl_3$): & 0.91 (6 H, d, J - 6.6 Hz), 1.20 - 1.30 (1H, m)., 1 47 (3H, t, J - 7.2 Hz), 1.51 - 1.72 (3H, m), 2.63 (2H, t, J - 7.8 Hz), 4.45 (2H, q, J - 7.2 Hz), 7.22 (2H, d, J - 8.4 Hz), 7.53- 7.64 (3H, m), 8.30 (1H, dd, J - 8.1 Hz, 2.1 Hz), 9.23 (1H, d, J - 2.1 Hz).

Ethyl 6-[4-(1,1,4-trimethylpentyl) phenylethynyl] nicotinate **(Compound 6a)**

Using the same general procedure as described for **Compound 3,** but using instead [4-(1,1,4-trimethylpentyl)] phenylethyne **(Compound 32),** the title compound was synthesized as a yellow oil. PMR ($CDCl_3$): & 0.83 (6H, d, J - 6.7 Hz), 0.88 - 0.99 (2H, m), 1.32 (6H, s), 1.35 - 1.50 (4H, m), 1 59 - 1.70 (2H, m), 4.45 (2H, q, J - 7.1 Hz), 7.36 (2H, d, J - 8.4 Hz), 7.55 - 7.64 (3H, m), 8.30 (1H, dd, J - 8.0 Hz, 2.2 Hz), 9.23 (1H, d, J - 2.2 Hz).

6-(3-Tert-butylphenylethynyl) nicotinic acid **(Compound 2)**

A solution of 60 mg (0.195 mmol) of ethyl 6-(3-tert-butylphenylethynyl) nicotinate **(Compound 1)** in 4 ml of aqueous ethanolic KOH was stirred at room temperature for 24 hours. The mixture was concentrated in-vacuo and the residue was treated with 5 ml of water and 5 ml of ether. The aqueous layer was separated and washed with a further 5 ml of ether. The aqueous layer was then acidified with 3 ml of 10 percent HCl and extracted with 2 x 5 ml of ether. The ether extracts were combined and washed with saturated NaCl solution and then dried ($MgSO_4$). The solution was concentrated in-vacuo to give the title compound as a pale yellow solid. PMR ($CDCl_3$): & 1.26 (9H, s), 7.25 (1H, t, J - 7.8 Hz), 7.35 - 7.42 (2H, m), 7.56 - 7.63 (2H, m), 8 35 (1H, dd, J - 8.2 H, 2.1 Hz), 9.31 (1H, d, J - 2 1 Hz).

4-Bromophenyl-tert-butyl-sulfide **(Compound 41)**

A constant flow of isobutylene was bubbled through a solution of 4 g (21.16 mmol) of 4-bromo-thiophenol **(Compound 40)** in 250 ml of methylene chloride under a nitrogen atmosphere and the mixture treated slowly with 0.6 ml of conc. H_2SO_4. Isobutylene was bubbled through the reaction mixture at room temperature for 2.5 hours and the mixture

then stirred for a further 12 hours. The mixture was then washed successively with saturated $NaHCO_3$, water, 1N HCl, water and saturated NaCl and then dried ($MgSO_4$). The solvent was then removed in-vacuo and the residue purified by flash chromatography (silica; 3% ethyl acetate in hexanes) to give the title compound as a colorless oil. PMR ($CDCl_3$): & 1.28 (9H, s), 7.39 (2H, d, J - 8.4 Hz), 7.47 (2H, d, J - 8.4 Hz).

3-Bromophenyl tert-butyl sulfide **(Compound 55)**

Isobutylene was bubbled through 75% H_2SO_4 solution at -5 degrees C until 2.65 g (47.2 mmol) of isobutylene had been absorbed. The mixture was treated with 3.8 g (20 1 mmol) of 3-bromothiophenol and then allowed to warm to room temperature and stirred for 72 hours. The reaction mixture was then poured into 40 ml of an ice/water mixture and then extracted with ether. The ether extracts were combined and washed successively with 5% NaOH, water and saturated NaCl solution and then dried ($MgSO_4$). The solvent was removed in-vacuo and the residue distilled (69 - 75 degrees C, 0.6 mm) to give the title compound as a pale yellow oil PMR ($CDCl_3$) : & 1.30 (9H, s), 7.23 (1H, t, J - 8.0 Hz), 7.45 - 7.54 (2H, m), 7.72 (1H, t, J - 1.8 Hz).

4-Bromophenyl 3-methyl-2-butenyl sulfide **(Compound 46)**

A mixture of 12.8 g (67.7 mmol) of 4-bromothiophenol **(Compound 40)** and 2.7 g (67.7 mmol) of sodium hydroxide in 50 ml acetone was heated at reflux under argon for 2.5 hours. The refluxing mixture was then treated dropwise with a solution of 10.0 g (67.1 mmol) of 4-bromo-2-methyl-2-butene **(Compound 45)** in 10 ml acetone and the mixture heated at reflux for a further 24 hours The mixture was then cooled and solvent removed in-vacuo. The residue was treated with 50 ml water and extracted with 3 x 75 ml ether. The ether extracts were combined and washed successively with 3 x 30 ml of 5% NaOH, 50 ml of water and 50 ml of saturated NaCl and then dried ($MgSO_4$). Solvent was then removed in-vacuo and the residual oil purified by kugelrohr distillation (70 degrees C, 0.1 mm) to give the title compound as a colourless oil. PMR ($CDCl_3$). & 1.58 (3H, s), 1.70 (3H, s) 3.5 (2H, d, J - 7.0 Hz), 5.27 (1H, t, J - 7.0 Hz), 7.17 (2H, d, J - 8.3 Hz), 7.36 (2H, d, J 8.3 Hz).

4-Bromophenyl 3-methylbutyl sulfide **(Compound 50)**

A mixture of 15 g (79 mmol) of 4-bromo-thiophenol **(Compound 40),** 3.16 g (79 mmol) of powdered sodium hydroxide and 150 ml of acetone was heated at reflux for 15 minutes. The refluxing mixture was then treated dropwise with a solution of 12 g (79 mmol) of 1-bromo-3-methylbutane **(Compound 49)** in 25 ml of acetone and then refluxed for a further 18 hours. The mixture was allowed to cool and the solvent removed in-vacuo. The residue was taken up in 25 ml of water and the mixture basified with 2N NaOH solution. The mixture was extracted with ether and the combined ether extracts washed successively with 1N NaOH, water and saturated NaCl and then dried ($MgSO_4$). The solvent was removed in-vacuo and the residue distilled (113 - 117 degrees C, 0.2 mm) to give the title compound as a colourless oil. PMR ($CDCl_3$). & 0.93 (6H, d, J - 6.6 Hz), 1.47 - 1.58 (2H, m), 1.65 - 1.80 (1H, m), 2 90 (2H, t, J - 7.8 Hz), 7.18 (2H, d, J - 8.6 Hz), 7 39 (2H, d, J - 8.6 Hz).

Trimethylsilyl (4-thio-tert-butoxyphenyl) ethyne **(Compound 42)**

A mixture of 1.25 g (5.1 mmol) of 4-bromophenyl tert-butyl sulfide **(Compound 41),** 500 mg (5.1 mmol) of trimethylsilyl acetylene **(Compound 16),** 100 mg (0.53 mmol) of cuprous iodide, 200 mg (0.28 mmol) of bis (triphenylphosphine) palladium (II) chloride and 1 ml of triethylamine was degassed and then heated under argon at 55 degrees C for 160 hours. The triethylamine was then removed under vacuum and the residue purified by flash chromatography (silica; hexanes) to give the title compound as a colourless oil. PMR ($CDCl_3$): & 0.20 (9H, s), 1.22 (9H, s), 7.32 - 7.42 (4H, AB quartet)

Trimethylsilyl (3-thio-tert-butoxphenyl) ethyne **(Compound 56)**

Using the same general procedure as described for **Compound 42,** but using instead 3-bromophenyl tert-butyl sulfide **(Compound 55)**, the title compound was synthesized as a pale yellow oil. PMR ($CDCl_3$): & 0.25 (9H, s), 1.25 (9H, s), 7.22 (1H, t, J - 8.0 Hz), 7.39 - 7.46 (2H, m), 7.62 (1H, s).

Trimethylsilyl [4-(3-methyl-thio-2-butenoxy) phenyl] ethyne **(Compound 47)**

Using the same general procedure as described for **Compound 42**, but using instead 4-bromophenyl 3-methyl-2-butenyl sulfide **(Compound 46)**, the title compound was synthesized as a pale yellow oil. PMR ($CDCl_3$): & 0.25

(9H, s), 1.62 (3H, s), 1.71 (3H, s), 3.55 (2H, d, J - 7.5 Hz), 5.28 (1H, t, J - 7.5 Hz), 7.21 (2H, d, J - 8.1 Hz), 7.36 (2H, d, J - 8.1 Hz).

Trimethylsilyl [4-(3-methyl-thiobutoxy) phenyl] ethyne **(Compound 51)**

Using the same general procedure, as described for **Compound 42**, but using instead 4-bromophenyl 3-methyl-butyl sulfide **(Compound 50)**, the title compound was synthesized as a colourless oil PMR ($CDCl_3$). & 0.25 (9H, s), 0.92 (6H, d, J - 6.6 Hz), 1.48 - 1 58 (2H, m), 1 65 - 1.79 (1H, m), 2 92 (2H, t, J - 7.8 Hz), 7.20 (2H, d, J - 8.4 Hz), 7.37 (2H, d, J- 8.4 Hz).

4-Thio-tert-butoxyphenyl ethyne **(Compound 39)**

To a solution of 850 mg (3 24 mmol) of trimethylsilyl 4-thio-tert-butoxyphenylethyne **(Compound 42)** in 3 ml of isopropanol was added 5 ml of 1N KOH solution and the mixture was stirred at room temperature for 16 hours. The mixture was extracted with ether and the combined ether extracts were washed successively with dilute HCl, water, saturated $NaHCO_3$ and NaCl solutions and then dried ($MgSO_4$) The solvent was removed in-vacuo to give the title compound as a pale yellow oil. PMR ($CDCl_3$): & 1.29 (9H, s), 3.16 (1H, s), 7 42 - 7.52 (4H, AB quartet).

3-Thio-tert-butoxyphenyl ethyne **(Compound 43)**

Using the same general procedure as described for **Compound 39**, but using instead trimethylsilyl 3-thio-tert-butoxyphenyl ethyne **(Compound 56)**, the title compound was synthesized as a colorless oil PMR ($CDCl_3$): & 1.30 (9H, s), 3.11 (1H, s), 7.31 (1H, t, J - 7.7 Hz), 7.48 - 7.56 (2H,m), 7.69 (1H, t, J - 1.7 Hz).

4-(3-Methyl-thio-2-butenoxy) phenyl ethyne **(Compound 44)**

Using the same general procedure as described for **Compound 39)**, but using instead trimethylsilyl 4-(3-methyl-thio-2-butenoxy) phenyl ethyne **(Compound 47)**, the title compound was synthesized as a pale yellow oil. PMR ($CDCl_3$): & 1.63 (3H, s), 1 72 (3H, s), 3 08 (1H, s), 3.56 (2H, d, J - 7.5 Hz), 5.29 (1H, t, J - 7.5 Hz), 7.23 (2H, d, J - 8.4 Hz), 7 38 (2H, d, J - 8.4 Hz).

4-(3-methyl-thiobutoxyl) phenyl ethyne **(Compound 48)**

Using the same general procedure as described for **Compound 39**, but using instead trimethylsilyl 4-(3-methylthiobutoxy) phenyl ethyne **(Compound 51)** the title compound was synthesized as a colourless oil. PMR ($CDCl_3$) & 0 93 (6H, d, J - 6.7 Hz), 1.49 - 1.60 (2H, m), 1.65 - 1 80 (1H, m), 2.93 (2H, t, J - 7 8 Hz), 7.22 (2H, d, J - 8.5 Hz), 7.39 (2H, d, J - 8 5 Hz).

Ethyl 6-(3-thio-tert-butoxyphenyl) ethynyl nicotinate **(Compound 7)**

A mixture of 198 mg (1.04 mmol) of 3-thio-tert-butoxyphenyl ethyne **(Compound 43)**, 193 mg (1.04 mmol) of ethyl 6-chloro-nicotinate **(Compound 54)**, 10 mg (0.05 mmol) of cuprous iodide, 20 mg (0.03 mmol) of bis (triphenylphosphine) palladium (II) chloride and 0.5 ml of triethylamine was degassed under nitrogen and heated at 55 - 60 degrees C for 40 hours. The triethylamine was removed under vacuum and the residue purified by flash chromatography (silica, 10% ethyl acetate in hexanes) to give the title compound as a pale brown solid. PMR ($CDCl_3$): & 1.31 (9H, s), 1.43 (3H, t, J - 7 2 Hz), 4.43 (2H, q, J - 7.2 Hz), 7.36 (1H, t, J - 7.8 Hz), 7.55 - 7.66 (3H, m), 7.81 (1H, t, J - 1.7 Hz), 8.31 (1H, dd, J - 8.2 Hz, 2.2 Hz), 9.22 (1H, d, J - 2.2 Hz).

Ethyl 6-(4-thio-tert-butoxyphenyl) ethynyl nicotinate **(Compound 9)**

Using the same general procedure as described for **Compound 7**, but using instead 4-thio-tert-butoxyphenyl ethyne **(Compound 39)**, the title compound was synthesized as a pale brown solid. PMR ($CDCl_3$): & 1.31 (9H, s), 1 43 (3H, t, J - 7.1 Hz) , 4.43 (2H, q, J - 7.1 Hz), 7 51 - 7.63 (5H, m), 8.30 (1H, dd, J - 8.1 Hz, 2 1 Hz), 9.22 (1H, d, J - 2 1 Hz)

Ethyl 6-(4-(3-methyl-thiobutoxy) phenyl ethynyl nicotinate **(Compound 57)**

Using the same general procedure as described for **Compound 7**, but using instead 4-(3-methyl-thiobutoxy) phenyl ethyne **(Compound 48)**, the title compound was synthesized as a brown solid. PMR ($CDCl_3$). & 0.93 (6H, d, J - 6.5

Hz) 1.42 (3H, t, J - 7.1 Hz), 1.53 - 1.62 (2H, m), 1.67 - 1.82 (1H, m), 2.93 - 3.00 (2H, m)., 7.26 (2H, d, J - 8.4 Hz), 7.52 (2H, d, J - 8.4 Hz), 7.58 (1H, d, J - 8.2 Hz) 8.29 (1H, dd, J - 8.2 Hz, 2.1 Hz), 9.20 (1H, d, J 2.1Hz).

Ethyl-6-[4-(3-methyl-thio-2-butenoxyl phenyl] ethynyl nicotinate **(Compound 11)**

Using the same general procedure as described for **Compound 7**, but using instead 4-(3-methyl-thio-2-butenoxy) phenyl ethyne **(Compound 44)**, the title compound was synthesized as a pale yellow solid. PMR ($CDCl_3$): & 1.43 (3H, t, J - 7.1 Hz), 1.66 (3H, s), 1 74 (3H, s), 3.59 (2H, d, J - 7.5 Hz), 4 43 (2H, q, J - 7.1 Hz), 5 31 (1H, t, J - 7 5 Hz), 7.28 (2H, d, J - 8.4 Hz), 7.51 (2H, d, J - 8.4 Hz), 7.58 (1H, d, J - 8.1 Hz), 8.28 (1H, dd, J - 8.1 Hz; 1.8 Hz), 9.20 (1H, d, J - 1.8 Hz).

6-[4-(3-methyl-thio-2-butenoxyl phenyl] ethynyl nicotinic acid **(Compound 12)**

Using the same general procedure as for Compound 2 but using instead ethyl 6-[4-(3-methyl-thio-2-butenoxy) phenyl] ethynyl nicotinate **(Compound 11)**, the title compound was prepared as a pale yellow solid PMR ($CDCl_3$) & 1.67 (3H, s), 1.75 (3H, s), 3.61 (2H, d, J - 7.5 Hz), 5.32 (1H, t, J - 7.5 Hz), 7.30 (2H, d, J - 8.4 Hz), 7.53 (2H, d, J - 8.4 Hz), 7.61 (1H, d, J - 8.7 Hz), 8.32 (1H, dd, J - 8.7 Hz, 2.1 Hz), 9.23 (1H, d, J - 2.1 Hz).

Using the method described for the preparation of ethyl 6-(4-tert butylphenyl)-ethynyl nicotinate **(Compound 3)**, but using other examples of reagents corresponding to **General Formula 2** and **General Formula 3**, respectively, numerous specific examples of compounds of the invention can be prepared. Still further, as examples, the ethyne compounds **(General Formula 2)** which were specifically described above, i e.

4-tert-butylphenyl ethyne **(Compound 19)**;
3-tert-butylphenyl ethyne **(Compound 22)**;
4-(4-methylpentyl)-phenylethyne **(Compound 26)**;
4-(1,1,4-trimethylpentyl)phenylethyne **(Compound 32)**;
4-thio-tert-butoxyphenyl ethyne **(Compound 39)**;
3-thio-tert-butoxyphenyl ethyne **(Compound 43)**
4-(3-methyl-thio-2-butenoxy)phenyl ethyne **(Compound 44)**;
4-(3-methyl-thiobutoxy)-phenyl ethyne **(Compound 48)**

can be coupled with the reagents **(General Formula 3)** noted above, i e. with

ethyl 2-(2-chloropyrid-5-yl)acetate;
ethyl 5-(2-chloropyrid-5-yl)pentanoate;
ethyl 2-(2-iodofur-5-yl)acetate;
ethyl 5-(2-iodofur-5-yl)pentanoate;
ethyl 2-(2-iodothien-5-yl)acetate;
ethyl 5-(2-iodothien-5-yl)pentanoate,
ethyl 2-(3-chloropyridazin-6-yl)acetate;
ethyl 5-(3-chloropyridazin-6-yl)pentanoate

to provide a large number of further examples of compounds of the invention.

Examples of Formulation for Topical Administration

Preferably the compounds of the invention may be administered topically using various formulations Such formulations may be as follows:

Ingredient	Weight/Percent
Solution	
Retinoid (active ingredient)	0.1
BHT	0.1
Alcohol USP	58 0
Polyethylene Glycol 400 NF	41.8

Continuation of the Table on the next page

(continued)

Ingredient	Weight/Percent
Gel	
Retinoid (active ingredient)	0.1
BHT	0.1
Alcohol USP	97.8
Hydroxypropyl Cellulose	2.0

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. A compound of the formula (1)



(1)

wherein

R_1-R_3 independently are hydrogen, C_{1-8} alkyl, cycloalkyl or lower alkenyl, A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, lower alkenyl, SR* or OR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl;
Y is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl or oxazolyl;
E is lower alkenyl, lower alkynyl, lower cycloalkyl, C_{1-8} branched chain alkyl, or is characterised by the formula $(CH_2)_n$ where n is 0-6,
and Z is H, OH, OR', OCOR', -COOH or a pharmaceutically acceptable salt, ester or amide thereof, $-CH_2OH$ or an ether or ester derivative thereof, or -CHO or an acetal derivative, or -COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, but excluding the compounds wherein when R_1, R_2, R_3, A and B are all hydrogen, Y is pyridyl.

2. A compound of Claim 1 wherein A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, or lower alkenyl.

3. A compound of Claim 2 wherein one of the A and B groups is C_{1-8} alkyl.

4. A compound of Claim 1 wherein one of the A and B groups is SR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl.

5. A compound of Claim 2 or Claim 3 or Claim 4 wherein R_1-R_3 all are hydrogen.

6. A compound of any one of the preceding claims wherein E is characterized by the formula $(CH_2)_n$ where n is 0-5.

7. A compound of any one of the preceding claims wherein Z is -COOH or a pharmaceutically acceptable salt, ester or amide thereof.

8. A compound according to Claim 7 wherein Z is a carboxylic acid ester.

9. A compound of any one of the preceding Claims wherein Y represents a pyridine ring.

10. A compound according to Claim 1 of the Formula



wherein

A and B and R_1-R_3 independently are hydrogen, C_{1-8} alkyl, cycloalkyl or lower alkenyl, with the proviso that one of A and B is not hydrogen;
n is 0-6;
and Z is H, -COOH or a pharmaceutically acceptable salt, ester or amide thereof, $-CH_2OH$ or an ether or ester derivative thereof, or -CHO or an acetal derivative, or -COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons.

11. A compound of Claim 10 wherein one of A and B is a branched chain C_{1-8} alkyl group and the other is hydrogen.

12. A compound according to Claim 1 of the Formula



wherein

R_1-R_3 independently are hydrogen, C_{1-8} alkyl, cycloalkyl or lower alkenyl, A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, lower alkenyl, or SR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl, with the proviso that one of A and B is SR*
n is 0-6
and Z is H, -COOH or a pharmaceutically acceptable salt, ester or amide thereof, $-CH_2OH$ or an ether or ester derivative thereof, or -CHO or an acetal derivative, or - COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons

13. A compound of the Claim 12 wherein one of A and B is characterised by the formula SR* where R* is branched chain C_{1-8} alkyl or lower alkenyl, and the other is hydrogen.

14. A compound of any one of Claims 10 to 13 wherein Z is COOR** where R** is hydrogen or C_{1-8} alkyl.

15. A compound of any one of Claims 10 to 14 wherein n is zero.

16. A compound of any one of Claims 10 to 15 wherein the ethynyl group is attached to the 2 position of the pyridine nucleus and the $(CH_2)_n$-Z group is attached to the 5 position of the pyridine nucleus.

17. A compound according to Claim 1 of the Formula



wherein

A and B are hydrogen, C_{1-8} alkyl, cycloalkyl or lower alkenyl, with the proviso that one of A and B is not hydrogen, and
R^{**} is C_{1-8} alkyl.

18. A compound according to Claim 17 wherein A is hydrogen and B is tertiary butyl; or wherein B is hydrogen and A is tertiary butyl; or wherein A is hydrogen and B is 4-methylpentyl.

19. A compound according to Claim 18 wherein R^* is ethyl, or a compound according to Claim 18 wherein R^* is hydrogen.

20. A compound according to Claim 1 of the formula



wherein

A and B independently are hydrogen C_{1-8} alkyl, cycloalkyl, lower alkenyl, or SR^* where R^* is C_{1-8} alkyl, cycloalkyl or lower alkenyl, with the proviso that one of A and B is SR^*, and
R^{**} is C_{1-8} alkyl.

21. A compound of Claim 20 wherein A is hydrogen and B is SR^* where R^* is tertiary butyl; or wherein B is hydrogen and A is SR^* where R^* is tertiary butyl; or wherein A is hydrogen and B is SR^* where R^* is 3-methyl-2-butenyl.

22. A compound of Claim 19 wherein R^{**} is ethyl; or a compound of Claim 19 wherein R^{**} is hydrogen.

23. A compound of the Formula (1)



wherein

R_1-R_3 independently are hydrogen, C_{1-8} alkyl, cycloalkyl or lower alkenyl, A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, lower alkenyl, SR* or OR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl;
Y is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl or oxazolyl;
E is lower alkenyl, lower alkynyl, lower cycloalkyl, C_{1-8} branched chain alkyl, or is characterised by the formula $(CH_2)_n$ where n is 0-6,
and Z is H, OH, OR', OCOR', -COOH or a pharmaceutically acceptable salt, ester or amide thereof, - CH_2OH or an ether or ester derivative thereof, or -CHO or an acetal derivative, or -COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, for use in medicine.

24. A compound for use in medicine, said compound being as defined in any one of Claims 1 to 22.

25. A compound for use in medicine as defined in Claim 23 or Claim 24, said compound being for use in treating skin disorders in a mammal.

26. The use of a compound of the formula (1) as defined in Claim 23, or a compound of the formula (1) as defined in any one of Claims 1 to 22, for the manufacture of a medicament for the treatment of skin disorders.

27. A pharmaceutical composition comprising a compound of the formula (1) as defined in Claim 23 or a compound of the formula (1) as defined in any one of Claims 1 to 22, and a pharmaceutically acceptable carrier.

Claims for the following Contracting States : ES, GR

1. A process for the preparation of a compound of the formula (1):



(1)

wherein

R_1-R_3 independently are hydrogen C_{1-8} alkyl, cycloalkyl or lower alkenyl, A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, lower alkenyl, SR* or OR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl;
Y is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl or oxazolyl;
E is lower alkenyl, lower alkynyl, lower cycloalkyl, C_{1-8} branched chain alkyl, or is characterized by the formula

$(CH_2)_n$ where n is 0-6,
and Z is H, OH, OR^1, COOH or a pharmaceutically acceptable salt, ester or amide thereof, $-CH_2OH$ or an ether or ester derivative thereof, or -CHO or an acetal derivative, or -COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbon atoms but excluding the compounds wherein when R_1, R_2, R_3, A and B are all hydrogen, Y is pyridyl; which process comprises reacting a compound of the formula 2, or a metal acetylide derivative thereof, with a compound of the formula 3, suitably protected as necessary, in the presence of a catalyst, wherein the compounds of the formulae 2 and 3 are as shown below:



Formula 2



Formula 3

wherein A, B, R_1 to R_3, Y and E are as hereinbefore defined, Z^1 is a group Z as hereinbefore defined or a protected derivative or precursor thereof; and X is a halogen; and thereafter where required deprotecting any protected function or converting a precursor group Z^1 into a group Z or optionally converting one compound of the formula (1) into another compound of the formula (1).

2. A process according to claim 1 wherein A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, or lower alkenyl.

3. A process according to claim 2 wherein one of the A and B groups is C_{1-8} alkyl.

4. A process according to claim 1 wherein one of the A and B groups is SR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl.

5. A process according to claim 2 or claim 3 or claim 4 wherein R_1-R_3 all are hydrogen.

6. A process according to any one of the preceding claims wherein E is characterised by the formula $(CH_2)_n$ where n is 0-5.

7. A process according to any one of the preceding claims wherein Z is -COOH or a pharmaceutically acceptable salt, ester or amide thereof.

8. A process according to claim 7 wherein Z is a carboxylic acid ester.

9. A process according to any one of the preceding claims wherein Y represents a pyridine ring.

10. A process according to claim 1 wherein the compound of the formula (1) has the formula



wherein

A and B and R_1-R_3 independently are hydrogen, C_{1-8} alkyl, cycloalkyl or lower alkenyl, with the proviso that one of A and B is not hydrogen;
n is 0-6;
and Z is H, -COOH or a pharmaceutically acceptable salt, ester or amide thereof, $-CH_2OH$ or an ether or ester derivative thereof, or -CHO or an acetal derivative, or - COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons.

11. A process according to claim 10 wherein one of A and B is a branched chain C_{1-8} alkyl group and the other is hydrogen.

12. A process according to claim 1 wherein the compound of the Formula (1) has the formula



wherein

R_1-R_3 independently are hydrogen C_{1-8} alkyl, cycloalkyl or lower alkenyl, A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, lower alkenyl, or SR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl, with the proviso that one of A and B is SR*;
n is 0-6
and Z is H, -COOH or a pharmaceutically acceptable salt, ester or amide thereof, $-CH_2OH$ or an ether or ester derivative thereof, or -CHO or an acetal derivative, or - COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons.

13. A process according to claim 12 wherein one of A and B is characterised by the formula SR* wherein R* is branched chain C_{1-8} alkyl or lower alkenyl, and the other is hydrogen.

14. A process according to any one of claims 10 to 13 wherein Z is COOR** where R* is hydrogen or C_{1-8} alkyl.

15. A process according to any one of claims 10 to 14 wherein n is zero.

16. A process according to any one of claims 10 to 15 wherein the ethynyl group is attached to the 2 position of the pyridine nucleus and the $(CH_2)_n$-Z group is attached to the 5 position of the pyridine nucleus.

17. A process according to claim 1 wherein the compound of the formula (1) has the formula



wherein

A and B are hydrogen, C_{1-8} alkyl, cycloalkyl or lower alkenyl, with the proviso that one of A and B is not hydrogen, and
R^{**} is C_{1-8} alkyl.

18. A process according to claim 17 wherein A is hydrogen and B is tertiary butyl, or wherein B is hydrogen and A is tertiary butyl; or wherein A is hydrogen and B is 4-methylpentyl.

19. A process according to claim 18 wherein R^* is ethyl; or a process according to claim 18 wherein R^* is hydrogen.

20. A process according to claim 1 wherein the compound of the formula (1) has the formula



wherein

A and B independently are hydrogen, C_{1-8} alkyl, cycloalkyl, lower alkenyl, or SR^* where R^* is C_{1-8} alkyl, cycloalkyl or lower alkenyl, with the proviso that one of A and B is SR^*, and
R^{**} is C_{1-8} alkyl.

21. A process according to claim 20 wherein A is hydrogen and B is SR^* where R^* is tertiary butyl; or wherein B is hydrogen and A is SR^* where R^* is tertiary butyl; or wherein A is hydrogen and B is SR^* where R^* is 3-methyl-2-butenyl.

22. A process according to claim 21 wherein R^{**} is ethyl; or a process according to claim 21 wherein R^{**} is hydrogen.

23. A process according to any one of the preceding claims wherein the catalyst is a palladium complex.

24. A process according to Claim 23 wherein the palladium complex is $Pd(PQ_3)_2Cl_2$ wherein Q is a phenyl group.

25. A process according to any one of the preceding claims wherein the metal acetylide is a zinc acetylide salt.

26. A process according to any one of the preceding claims wherein the compound of the formula 2 is an acetylene derivative, and the reaction is carried out in the presence of cuprous iodide and an acid acceptor such as triethylamine.

27. A process for the preparation of a compound of the formula (1), said compound being as defined in any one of claims 1 to 22 which process comprises the conversion of a compound of the formula (4):



Formula 4

wherein A, B , R_1, R_2, R_3, Y and E are as defined in the preceding claims 1 to 22 and Z^1 is a precursor to the group Z defined therein.

28. A process for the preparation of a pharmaceutical composition comprising bringing a compound of the formula (1) as defined in any one of claims 1 to 22 into association with a pharmaceutically acceptable carrier.

29. The use of a compound of the formula (1):



wherein

R_1-R_3 independently are hydrogen C_{1-8} alkyl, cycloalkyl or lower alkenyl, A and B independently ar hydrogen, C_{1-8} alkyl, cycloalkyl, lower alkenyl, SR* or OR* where R* is C_{1-8} alkyl, cycloalkyl or lower alkenyl;
Y is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl or oxazolyl;
E is lower alkenyl, lower alkynyl, lower cycloalkyl, C_{1-8} branched chain alkyl, or is characterized by the formula $(CH_2)_n$ where n is 0-6,
and Z is H, OH, OR', COOH or a pharmaceutically acceptable salt, ester or amide thereof, $-CH_2OH$ or an ether or ester derivative thereof, or -CHO or an acetal derivative, or COR' or a ketal derivative where R' is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbon atoms; for the manufacture of a medicament for the treatment of skin disorders.

30. The use according to claim 29 wherein the compound of the formula (1) is a compound of the formula (1) as defined in any one of claims 1 to 22.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Verbindung der Formel (1)



(1)

in welcher

R_1-R_3 unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl, A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl, niedermolekulares Alkenyl, SR* oder OR* sind, wobei R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist;

Y Pyridyl, Thienyl, Furyl, Pyridazinyl, Pyrimidinyl, Pyrazinyl, Thiazolyl oder Oxazolyl ist;

E niedermolekulares Alkenyl, niedermolekulares Alkinyl, niedermolekulares Cycloalkyl, C_{1-8}-Alkyl mit verzweigter Kette ist oder durch die Formel $(CH_2)_n$ gekennzeichnet ist, wobei n einen Wert im Bereich von 0 bis 6 besitzt,

und Z H, OH, OR', OCOR', -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon, $-CH_2OH$ oder ein Äther- oder ein Esterderivat hiervon, oder -CHO oder ein Acetalderivat, oder -COR' oder ein Ketalderivat ist, wobei R' eine Alkyl-, Cycloalkyl- oder Alkenylgruppe mit 1 bis 5 Kohlenstoffatomen ist, jedoch unter Ausschluß der Verbindungen, bei welchen, wenn R_1, R_2, R_3, A und B sämtlich Wasserstoff sind, Y Pyridyl ist.

2. Verbindung nach Anspruch 1, bei welcher A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl sind.

3. Verbindung nach Anspruch 2, bei welcher eine der A-und B-Gruppen C_{1-8}-Alkyl ist.

4. Verbindung nach Anspruch 1, bei welcher eine der A-und B-Gruppen SR* ist, wobei R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist.

5. Verbindung nach Anspruch 2 oder Anspruch 3 oder Anspruch 4, bei welcher R_1 bis R_3 sämtlich Wasserstoff sind.

6. Verbindung nach einem der vorhergehenden Ansprüche, bei welcher E durch die Formel $(CH_2)_n$ gekennzeichnet ist, wobei n einen Wert im Bereich von 0 bis 5 besitzt.

7. Verbindung nach einem der vorhergehenden Ansprüche, bei welcher Z -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon ist.

8. Verbindung nach Anspruch 7, bei welcher Z ein Carboxylsäureester ist.

9. Verbindung nach einem der vorhergehenden Ansprüche, bei welcher Y einen Pyridinring darstellt.

10. Verbindung nach Anspruch 1 mit der Formel



in welcher

A und B und R_1-R_3 unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl sind, mit der Maßgabe, daß von A und B eines nicht Wasserstoff ist;

n einen Wert im Bereich von 0 bis 6 besitzt;

und Z H, -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon, $-CH_2OH$ oder ein Äther- oder ein Esterderivat hiervon, oder -CHO oder ein Acetalderivat, oder -COR' oder ein Ketalderivat ist, wobei R' eine Alkyl-, Cycloalkyl- oder Alkenylgruppe mit 1 bis 5 Kohlenstoffen ist.

11. Verbindung nach Anspruch 10, in welcher eines von A und B eine C_{1-8}-Alkylgruppe mit verzweigter Kette und das andere Wasserstoff ist.

12. Verbindung nach Anspruch 1 mit der Formel



in welcher

R_1-R_3 unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl, A und B unabhangig voneinander Wasserstoff, C_{1-6}-Alkyl, Cycloalkyl, niedermolekulares Alkenyl oder SR* ist, wobei R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist, mit der Maßgabe, daß von A und B eines SR* ist

n einen Wert im Bereich von 0 bis 6 besitzt

und Z H, -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon, $-CH_2OH$ oder ein Äther- oder Esterderivat hiervon, oder -CHO oder ein Acetalderivat, oder -COR' oder ein Ketalderivat ist, wobei R' eine Alkyl-, Cycloalkyl- oder Alkenylgruppe mit 1 bis 5 Kohlenstoffatomen ist.

13. Verbindung nach Anspruch 12, bei welcher von A und B eines durch die Formel SR* gekennzeichnet ist, wobei R* C_{1-8}-Alkyl mit verzweigter Kette oder niedermolekulares Alkenyl, und das andere Wasserstoff ist.

14. Verbindung nach einem der Ansprüche 10 bis 13, bei welcher Z COOR** ist, wobei R** Wasserstoff oder C_{1-8}-Alkyl ist.

15. Verbindung nach einem der Ansprüche 10 bis 14, bei welcher n den Wert 0 besitzt.

16. Verbindung nach einem der Ansprüche 10 bis 15, bei welcher die Äthinylgruppe an die 2-Stelle des Pyridinkerns und die $(CH_2)_n$-Z-Gruppe an die 5-Stelle des Pyridinkerns gebunden ist.

17. Verbindung nach Anspruch 1 mit der Formel



in welcher

A und B Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl sind, mit der Maßgabe, daß von A und B eines nicht Wasserstoff ist und

R** C_{1-8}-Alkyl ist.

18. Verbindung nach Anspruch 17, bei welcher A Wasserstoff und B tertiäres Butyl ist; oder bei welcher B Wasserstoff und A tertiäres Butyl ist, oder bei welcher A Wasserstoff und B 4-Methylpentyl ist.

19. Verbindung nach Anspruch 18, bei welcher R* Äthyl ist; oder eine Verbindung nach Anspruch 18, bei welcher R* Wasserstoff ist.

20. Verbindung nach Anspruch 1 mit der Formel



in welcher

A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl, niedermolekulares Alkenyl oder SR* ist, worin R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist, mit der Maßgabe, daß von A und B eines SR* ist, und

R** C_{1-8}-Alkyl ist.

21. Verbindung nach Anspruch 20, bei welcher A Wasserstoff und B SR* ist, worin R* tertiäres Butyl ist; oder bei welcher

B Wasserstoff und A SR*, wobei R* tertiäres Butyl ist; oder bei welcher A Wasserstoff und B SR* ist, wobei R* 3-Methyl-2-Butenyl ist.

22. Verbindung nach Anspruch 19, bei welcher R** Ethyl ist; oder eine Verbindung nach Anspruch 19, bei welcher R** Wasserstoff ist.

23. Verbindung der Formel (1)



in welcher

R_1-R_3 unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl, A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl, niedermolekulares Alkenyl, SR* oder OR* sind, wobei R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist;

Y Pyridyl, Thienyl, Furyl, Pyridazinyl, Pyrimidinyl, Pyrazinyl, Thiazolyl oder Oxazolyl ist;

E niedermolekulares Alkenyl, niedermolekulares Alkinyl, niedermolekulares Cycloalkyl, C_{1-8}-Alkyl mit verzweigter Kette ist oder durch die Formel $(CH_2)_n$ gekennzeichnet ist, wobei n einen Wert im Bereich von 0 bis 6 besitzt,

und Z H, OH, OR', OCOR', -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon, $-CH_2OH$ oder ein Äther- oder ein Esterderivat hiervon, oder -CHO oder ein Acetalderivat, oder -COR' oder ein Ketalderivat ist, wobei R' eine Alkyl-, Cycloalkyl- oder Alkenylgruppe mit 1 bis 5 Kohlenststoffatomen ist, zur Verwendung in der Medizin.

24. Verbindung zur Verwendung in der Medizin, wobei die genannte Verbindung wie in einem der Ansprüche 1 bis 22 definiert ist.

25. Verbindung zur Verwendung in der Medizin wie in Anspruch 23 oder Anspruch 24 definiert, wobei die genannte Verbindung zur Verwendung bei der Behandlung von Hautstörungen bzw. -erkrankungen in einem Säugetier dient.

26. Verwendung einer Verbindung der Formel (1) wie in Anspruch 23 definiert, oder einer Verbindung der Formel (1) wie in einem der Ansprüche 1 bis 22 definiert, zur Herstellung eines Medikaments für die Behandlung von Hautstörungen bzw. -erkrankungen.

27. Pharmazeutische Zusammensetzung, welche eine Verbindung der Formel (1) wie in Anspruch 23 definiert, oder eine Verbindung der Formel (1) wie in einem der Ansprüche 1 bis 22 definiert, und einen pharmazeutisch verträglichen Träger aufweist.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung einer Verbindung der Formel (1):



(1)

in welcher

R_1-R_3 unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl, A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl, niedermolekulares Alkenyl, SR* oder OR* sind, wobei R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist;

Y Pyridyl, Thienyl, Furyl, Pyridazinyl, Pyrimidinyl, Pyrazinyl, Thiazolyl oder Oxazolyl ist;

E niedermolekulares Alkenyl, niedermolekulares Alkinyl, niedermolekulares Cycloalkyl, C_{1-8}-Alkyl mit verzweigter Kette ist oder durch die Formel $(CH_2)_n$ gekennzeichnet ist, wobei n einen Wert im Bereich von 0 bis 6 besitzt,

und Z H, OH, OR^1, OCOR', COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon, $-CH_2OH$ oder ein Äther- oder ein Esterderivat hiervon, oder -CHO oder ein Acetalderivat, oder -COR' oder ein Ketalderivat ist, wobei R' eine Alkyl-, Cycloalkyl- oder Alkenylgruppe mit 1 bis 5 Kohlenstoffatomen ist, jedoch unter Ausschluß der Verbindungen, bei welchen, wenn R_1, R_2, R_3, A und B sämtlich Wasserstoff sind, Y Pyridyl ist, wobei das Verfahren umfaßt, daß man eine Verbindung der Formel 2, oder ein Metallacetylidderivat hiervon, mit einer Verbindung der Formel 3, gegebenenfalls in erforderlicher Weise geschützt, in Gegenwart eines Katalysators zur Reaktion bringt, wobei die Verbindungen der Formel 2 und Formel 3 wie folgt sind:



Formel 2



Formel 3

worin A, B, R_1 bis R_3, Y und E wie oben definiert sind, Z^1 eine Gruppe Z wie oben definiert oder ein geschütztes Derivat oder ein Vorläufer hierfür ist; und X ein Halogen ist; und daß man danach soweit erforderlich jeweils jede geschützte Funktion entschützt oder eine Vorläufergruppe Z^1 in eine Gruppe Z umwandelt oder wahlweise eine Verbindung der Formel (1) in eine andere Verbindung der Formel (1) umwandelt.

2. Verfahren nach Anspruch 1, bei welchem A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl sind.

3. Verfahren nach Anspruch 2, bei welchem eine der A-und B-Gruppen C_{1-8}-Alkyl ist.

4. Verfahren nach Anspruch 1, bei welchem eine der A-und Gruppen SR* ist, wobei R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist.

5. Verbindung nach Anspruch 2 oder Anspruch 3 oder Anspruch 4, bei welcher R^1 bis R^3 sämtlich Wasserstoff sind

6. Verfahren nach einem der vorhergehenden Ansprüche, bei welchem E durch die Formel $(CH_2)_n$ gekennzeichnet ist, wobei n einen Wert im Bereich von 0 bis 5 besitzt

7. Verfahren nach einem der vorhergehenden Ansprüche, bei welchem Z -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon ist.

8. Verfahren nach Anspruch 7, bei welchem Z ein Carboxylsäureester ist.

9. Verfahren nach einem der vorhergehenden Ansprüche, bei welchem Y einen Pyridinring darstellt.

10. Verfahren nach Anspruch 1, bei welchem die Verbindung der Formel (1) die Formel



besitzt, in welcher

A und B und R_1-R_3 unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl sind, mit der Maßgabe, daß von A und B eines nicht Wasserstoff ist;

n einen Wert im Bereich von 0 bis 6 besitzt;

und Z H, -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon, $-CH_2OH$ oder ein Äther- oder ein Esterderivat hiervon, oder -CHO oder ein Acetalderivat, oder -COR' oder ein Ketalderivat ist, wobei R' eine Alkyl-, Cycloalkyl- oder Alkenylgruppe mit 1 bis 5 Kohlenstoffen ist.

11. Verfahren nach Anspruch 10, in welchem von A und B eines eine C_{1-8}-Alkylgruppe mit verzweigter Kette und das andere Wasserstoff ist.

12. Verfahren nach Anspruch 1, bei welchem die Verbindung der Formel (1) die Formel



besitzt, in welcher

R_1-R_3 unabhangig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl, A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl, niedermolekulares Alkenyl oder SR* ist, wobei R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist, mit der Maßgabe, daß von A und B eines SR* ist

n einen Wert im Bereich von 0 bis 6 besitzt

und Z H, -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon, $-CH_2OH$ oder ein Äther- oder Esterderivat hiervon, oder -CHO oder ein Acetalderivat, oder -COR' oder ein Ketalderivat ist, wobei R' eine Alkyl-, Cycloalkyl- oder Alkenylgruppe mit 1 bis 5 Kohlenstoffatomen ist.

13. Verfahren nach Anspruch 12, bei welchem von A und B eines durch die Formel SR* gekennzeichnet ist, wobei R* C_{1-8}-Alkyl mit verzweigter Kette oder niedermolekulares Alkenyl, und das andere Wasserstoff ist.

14. Verfahren nach einem der Ansprüche 10 bis 13, bei welchem Z COOR** ist, wobei R** Wasserstoff oder C_{1-8}-Alkyl ist.

15. Verfahren nach einem der Ansprüche 10 bis 14, bei welchem n den Wert 0 besitzt.

16. Verfahren nach einem der Ansprüche 10 bis 15, bei welchem die Äthinylgruppe an die 2-Stelle des Pyridinkerns und die $(CH_2)_n$-Z-Gruppe an die 5-Stelle des Pyridinkerns gebunden ist.

17. Verfahren nach Anspruch 1, bei welchem die Verbindung der Formel (1) die Formel



besitzt, in welcher

A und B Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl sind, mit der Maßgabe, daß von A und B eines nicht Wasserstoff ist und

R** C_{1-8}-Alkyl ist.

18. Verfahren nach Anspruch 17, bei welchem A Wasserstoff und B tertiäres Butyl ist; oder bei welchem B Wasserstoff und A tertiäres Butyl ist; oder bei welchem A Wasserstoff und B 4-Methylpentyl ist.

19. Verfahren nach Anspruch 18, bei welchem R* Äthyl ist; oder ein Verfahren nach Anspruch 18, bei welchem R* Wasserstoff ist.

20. Verfahren nach Anspruch 1, bei welchem die Verbindung der Formel (1) die Formel



besitzt, in welcher

A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl, niedermolekulares Alkenyl oder SR* ist, worin R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist, mit der Maßgabe, daß von A und B eines SR* ist, und

R** C_{1-8}-Alkyl ist.

21. Verfahren nach Anspruch 20, bei welchem A Wasserstoff und B SR* ist, worin R* tertiäres Butyl ist; oder bei welchem B Wasserstoff und A SR*, wobei R* tertiäres Butyl ist, oder bei welchem A Wasserstoff und B SR* ist, wobei R* 3-Methyl-2-Butenyl ist.

22. Verfahren nach Anspruch 21, bei welchem R** Ethyl ist; oder ein Verfahren nach Anspruch 22, bei welchem R** Wasserstoff ist.

23. Verfahren nach einem der vorhergehenden Ansprüche, bei welchem der Katalysator ein Palladiumkomplex ist.

24. Verfahren nach Anspruch 23, bei welchem der Palladiumkomplex $Pd(PQ_3)_2Cl_2$ ist, wobei Q eine Phenylgruppe ist

25. Verfahren nach einem der vorhergehenden Ansprüche, bei welchem das Metallacetylid ein Zinkacetylidsalz ist.

26. Verfahren nach einem der vorhergehenden Ansprüche, bei welchem die Verbindung der Formel (2) ein Acetylenderivat ist und die Reaktion in Gegenwart von Kupferjodid und einem Saureakzeptor wie beispielsweise Triäthylamin durchgeführt wird.

27. Verfahren zur Herstellung einer Verbindung der Formel (1), wobei die genannte Verbindung wie in einem der Ansprüche 1 bis 22 definiert ist, und wobei das Verfahren die Umwandlung einer Verbindung der Formel (4)



Formel 4

umfaßt, wobei A, B, R_1, R_2, R_3, Y und E, die in den vorhergehenden Ansprüchen 1 bis 22 definiert sind und Z^1 ein Vorläufer der darin definierten Gruppe Z ist.

28. Verfahren zur Herstellung einer Zubereitung einer pharmazeutischen Zusammensetzung, welches umfaßt, daß

man eine Verbindung der Formel (1), wie in einem der Ansprüche 1 bis 22 definiert, in Zuordnung zu einem pharmazeutisch verträglichen Träger bringt

29. Verwendung einer Verbindung der Formel (1):



in welcher

R_1-R_3- unabhangig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl, A und B unabhängig voneinander Wasserstoff, C_{1-8}-Alkyl, Cycloalkyl, niedermolekulares Alkenyl, SR* oder OR* sind, wobei R* C_{1-8}-Alkyl, Cycloalkyl oder niedermolekulares Alkenyl ist;

Y Pyridyl, Thienyl, Furyl, Pyridazinyl, Pyrimidinyl, Pyrazinyl, Thiazolyl oder Oxazolyl ist;

E niedermolekulares Alkenyl, niedermolekulares Alkinyl, niedermolekulares Cycloalkyl, C_{1-8}-Alkyl mit verzweigter Kette ist oder durch die Formel $(CH_2)_n$ gekennzeichnet ist, wobei n einen Wert im Bereich von 0 bis 6 besitzt,

und Z H, OH, OR', -COOH oder ein pharmazeutisch verträgliches Salz, Ester oder Amid hiervon, $-CH_2OH$ oder ein Äther- oder ein Esterderivat hiervon, oder -CHO oder ein Acetalderivat, oder -COR' oder ein Ketalderivat ist, wobei R' eine Alkyl-, Cycloalkyl- oder Alkenylgruppe mit 1 bis 5 Kohlenststoffatomen ist; zur Herstellung eines Medikaments für die Behandlung von Hautstörungen bzw. -erkrankungen.

30. Verwendung nach Anspruch 29, bei welcher die Verbindung der Formel (1) eine Verbindung der Formel (1) wie in einem der Ansprüche 1 bis 22 definiert ist.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Composé de formule (1) .



(1)

où

R_1-R_3 sont indépendamment l'atome d'hydrogène, un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, A et B sont indépendamment l'atome d'hydrogène, un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, SR* ou OR* où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8} ,
Y est un groupe pyridyle, thiényle, furyle, pyridazinyle, pyrimidinyle, pyrazinyle, thiazolyle ou oxazolyle ;
E est un groupe alkényle inférieur, alkynyle inférieur, cyclo-alcoyle inférieur ou alcoyle en C_{1-8} à chaîne ramifiée, ou est un groupe caractérisé par la formule $(CH_2)_n$ où n est un nombre entier de 0 à 6,
et Z est H, OH, OR', OCOR', -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique, -CH_2OH ou l'un de ses dérivés éther ou ester, -CHO ou l'un de ses dérivés acétal, ou -COR' ou l'un de ses dérivés cétal, où R' est un groupe alcoyle, cyclo-alcoyle ou alkényle de 1 à 5 atomes de carbone, à l'exclusion des composés dans lesquels, lorsque R_1, R_2, R_3, A et B sont tous l'atome d'hydrogène, Y est un groupe pyridyle.

2. Composé selon la revendication 1, dans lequel A et B sont indépendamment l'atome d'hydrogène, ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}.

3. Composé selon la revendication 2, dans lequel l'un des radicaux A et B est un groupe alcoyle en C_{1-8}.

4. Composé selon la revendication 1, dans lequel l'un des radicaux A et B est SR*, où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}.

5. Composé selon la revendication 2 ou la revendication 3 ou la revendication 4, dans lequel R_1-R_3 sont tous l'atome d'hydrogène.

6. Composé selon l'une des revendications précédentes, dans lequel E est un groupe caractérisé par la formule $(CH_2)_n$, où n est un nombre entier de 0 à 5.

7. Composé selon l'une des revendications précédentes, dans lequel Z est -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique.

8. Composé selon la revendication 7, dans lequel Z est un ester d'acide carboxylique

9. Composé selon l'une des revendications précédentes, dans lequel Y représente un cycle pyridine.

10. Composé selon la revendication 1 de formule :



où

A et B et R_1-R_3 sont indépendamment l'atome d'hydrogène, un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, à la condition que l'un des radicaux A et B ne soit pas l'atome d'hydrogène ;
n est un nombre entier de 0 à 6 ;
et Z est H, -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique, -CH_2OH ou l'un de ses dérivés éther ou ester, -CHO ou l'un de ses dérivés acétal, ou -COR' ou l'un de ses dérivés cétal, où R' est un groupe alcoyle, cyclo-alcoyle ou alkényle de 1 à 5 atomes de carbone.

11. Composé selon la revendication 10 dans lequel l'un des radicaux A et B est un groupe alcoyle en C_{1-8} à chaîne ramifiée et l'autre est l'atome d'hydrogène.

12. Composé selon la revendication 1 de formule :



où

R_1-R_3 sont indépendamment l'atome d'hydrogène, un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, A et B sont indépendamment l'atome d'hydrogène, un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, ou SR* où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, à la condition que l'un des radicaux A et B soit SR* ;
n est un nombre entier de 0 à 6 ;
et Z est H, -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique, $-CH_2OH$ ou l'un de ses dérivés éther ou ester, -CHO ou l'un de ses dérivés acétal, ou -COR' ou l'un de ses dérivés cétal, où R' est un groupe alcoyle, cyclo-alcoyle ou alkényle de 1 à 5 atomes de carbone.

13. Composé selon la revendication 12, dans lequel l'un des radicaux A et B est caractérisé par la formule SR* où R* est un groupe alcoyle ou alkényle inférieur en C_{1-8} à chaîne ramifiée, et l'autre est l'atome d'hydrogène.

14. Composé selon l'une des revendications 10 à 13, dans lequel Z est COOR**, où R** est l'atome d'hydrogène ou un groupe alcoyle en C_{1-8}.

15. Composé selon l'une des revendications 10 à 14, dans lequel n est zéro.

16. Composé selon l'une des revendications 10 à 15, dans lequel le groupe éthynyle occupe la position 2 du noyau pyridine et le groupe $(CH_2)_n$-Z occupe la position 5 du noyau pyridine

17. Composé selon la revendication 1 de formule :



où

A et B sont l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, à la condition que l'un des radicaux A et B ne soit pas l'atome d'hydrogène, et
R** est un groupe alcoyle en C_{1-8}.

18. Composé selon la revendication 17, dans lequel A est l'atome d'hydrogène et B est un groupe butyle tertiaire ; ou

dans lequel B est l'atome d'hydrogène et A est un groupe butyle tertiaire ; ou dans lequel A est l'atome d'hydrogène et B est un groupe 4-méthylpentyle.

19. Composé selon la revendication 18, dans lequel R* est le groupe éthyle ; ou composé selon la revendication 18 dans lequel R* est l'atome d'hydrogène.

20. Composé selon la revendication 1 de formule



où

A et B sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, ou SR* où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, à la condition que l'un des radicaux A et B soit SR* ; et
R** est un groupe alcoyle en C_{1-8}.

21. Composé selon la revendication 20, dans lequel A est l'atome d'hydrogène et B est SR* où R* est un groupe butyle tertiaire ; ou dans lequel B est l'atome d'hydrogène et A est SR* où R* est un groupe butyle tertiaire ; ou dans lequel A est l'atome d'hydrogène et B est SR* où R* est le groupe 3-méthyl-2-butényle.

22. Composé selon la revendication 19, dans lequel R** est le groupe éthyle , ou composé selon la revendication 19, dans lequel R** est l'atome d'hydrogène.

23. Composé de formule (1) :



(1)

où

R_1-R_3 sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, A et B sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, SR* ou OR* où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8} ;
Y est un groupe pyridyle, thiényle, furyle, pyridazinyle, pyrimidinyle, pyrazinyle, thiazolyle ou oxazolyle ;
E est un groupe alkényle inférieur, alkynyle inférieur, cyclo-alcoyle inférieur, ou alcoyle en C_{1-8} à chaîne ramifiée, ou est un groupe caractérisé par la formule $(CH_2)_n$ où n est un nombre entier de 0 à 6,
et Z est H, OH, OR', OCOR', -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique, $-CH_2OH$ ou l'un de ses dérivés éther ou ester, ou -CHO ou l'un de ses dérivés acétal, ou -COR' ou l'un de ses dérivés cétal, où R' est un groupe alcoyle, cyclo-alcoyle ou alkényle de 1 à 5 atomes de carbone,

destiné à être utilisé en médecine.

24. Composé destiné à être utilisé en médecine, ledit composé étant tel que défini dans l'une des revendications 1 à 22.

25. Composé destiné à être utilisé en médecine tel que défini dans la revendication 23 ou la revendication 24, ledit composé étant destiné à traiter des maladies de la peau chez un mammifère.

26. Utilisation d'un composé de formule (1) tel que défini dans la revendication 23, ou d'un composé de formule (1) tel que défini dans l'une des revendications 1 à 22, dans la fabrication d'un médicament destiné au traitement de maladies de la peau.

27. Composition pharmaceutique comprenant un composé de formule (1) tel que défini dans la revendication 23 ou un composé de formule (1) tel que défini dans l'une des revendications 1 à 22, et un véhicule acceptable sur le plan pharmaceutique.

Revendications pour les Etats contractants suivants : ES, GR

1. Procédé de préparation d'un composé de formule(1).



(1)

où

R_1-R_3 sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, A et B sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, SR* ou OR* où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8} ;
Y est un groupe pyridyle, thiényle, furyle, pyridazinyle, pyrimidinyle, pyrazinyle, thiazolyle ou oxazolyle ;
E est un groupe alkényle inférieur, alkynyle inférieur, cyclo-alcoyle inférieur ou alcoyle en C_{1-8} à chaîne ramifiée, ou est un groupe caractérisé par la formule $(CH_2)_n$ où n est un nombre entier de 0 à 6,
et Z est H, OH, OR^1, COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique, $-CH_2OH$ ou l'un de ses dérivés éther ou ester, -CHO ou l'un de ses dérivés acétal, ou -COR' ou l'un de ses dérivés cétal, où R' est un groupe alcoyle, cyclo-alcoyle ou alkényle de 1 à 5 atomes de carbone, à l'exclusion des composés dans lesquels, lorsque R_1, R_2 , R_3 A et B sont tous l'atome d'hydrogène, Y est un groupe pyridyle ; lequel procédé comprend la réaction d'un composé de formule 2, ou de l'un de ses dérivés acétylure métallique, et d'un composé de formule 3, convenablement protégé si nécessaire, en présence d'un catalyseur, dans lequel les composés des formules 2 et 3 sont tels qu'illustrés ci-dessous :



Formule 2



Formule 3

où A, B, R_1 à R_3, Y et E sont tels que définis ci-dessus, Z^1 est un groupe Z tel que défini ci-dessus ou l'un de ses dérivés protégés ou précurseurs ; et X est un atome d'halogène ; et ensuite, le cas échéant, la déprotection de toute fonction protégée ou la conversion d'un groupe précurseur Z^1 en un groupe Z, ou facultativement la conversion d'un composé de formule (1) en un autre composé de formule (1).

2. Procédé selon la revendication 1, dans lequel A et B sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}.

3. Procédé selon la revendication 2, dans lequel l'un des radicaux A et B est un groupe alcoyle en C_{1-8}.

4. Procédé selon la revendication 1, dans lequel l'un des radicaux A et B est SR*, où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}.

5. Procédé selon la revendication 2 ou la revendication 3 ou la revendication 4, dans lequel R_1-R_3 sont tous l'atome d'hydrogène.

6. Procédé selon l'une des revendications précédentes, dans lequel E est un groupe caractérisé par la formule $(CH_2)_n$, où n est un nombre entier de 0 à 5.

7. Procédé selon l'une des revendications précédentes, dans lequel Z est -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique.

8. Procédé selon la revendication 7, dans lequel Z est un ester d'acide carboxylique.

9. Procédé selon l'une des revendications précédentes, dans lequel Y représente un cycle pyridine.

10. Procédé selon la revendication 1, dans lequel le composé de formule (1) correspond à la formule :



où

A et B et R_1-R_3 sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, à la condition que l'un des radicaux A et B ne soit pas l'atome d'hydrogène ,
n est un nombre entier de 0 à 6 ;
et Z est H, -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique, $-CH_2OH$ ou l'un de ses dérivés éther ou ester, -CHO ou l'un de ses dérivés acétal, ou -COR' ou l'un de ses dérivés cétal, où R' est un groupe alcoyle, cyclo-alcoyle ou alkényle de 1 à 5 atomes de carbone.

11. Procédé selon la revendication 10, dans lequel l'un des radicaux A et B est un groupe alcoyle en C_{1-8} à chaîne ramifiée et l'autre est l'atome d'hydrogène.

12. Procédé selon la revendication 1 dans lequel le composé de formule (1) correspond à la formule :



où

R_1-R_3 sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, A et B sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, ou SR* où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, à la condition que l'un des radicaux A et B soit SR* ;
n est un nombre entier de 0 à 6 ;
et Z est H, -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique, $-CH_2OH$ ou l'un de ses dérivés éther ou ester, -CHO ou l'un de ses dérivés acétal, ou -COR' ou l'un de ses dérivés cétal, où R' est un groupe alcoyle, cyclo-alcoyle ou alkényle de 1 à 5 atomes de carbone.

13. Procédé selon la revendication 12, dans lequel l'un des radicaux A et B est caractérisé par la formule SR* où R* est un groupe alcoyle ou alkényle inférieur en C_{1-8} à chaîne ramifiée, et l'autre est l'atome d'hydrogène.

14. Procédé selon l'une des revendications 10 à 13, dans lequel Z est COOR**, où R** est l'atome d'hydrogène ou un groupe alcoyle en C_{1-8}.

15. Procédé selon l'une des revendications 10 à 14, dans lequel n est zéro.

16. Procédé selon l'une des revendications 10 à 15, dans lequel le groupe éthynyle occupe la position 2 du noyau pyridine et le groupe $(CH_2)_n$-Z occupe la position 5 du noyau pyridine.

17. Procédé selon la revendication 1, dans lequel le composé de formule (1) correspond à la formule :



où

A et B sont l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, à la condition que l'un des radicaux A et B ne soit pas l'atome d'hydrogène, et
R** est un groupe alcoyle en C_{1-8}.

18. Procédé selon la revendication 17, dans lequel À est l'atome d'hydrogène et B est un groupe butyle tertiaire ; ou dans lequel B est l'atome d'hydrogène et A est un groupe butyle tertiaire , ou dans lequel A est l'atome d'hydrogène et B est un groupe 4-méthylpentyle.

19. Procédé selon la revendication 18, dans lequel R* est le groupe éthyle ; ou procédé selon la revendication 18, dans lequel R* est l'atome d'hydrogène.

20. Procédé selon la revendication 1, dans lequel le composé de formule (1) correspond à la formule :



où

A et B sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, ou SR* où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, à la condition que l'un des radicaux A et B soit SR* ; et
R** est un groupe alcoyle en C_{1-8}.

21. Procédé selon la revendication 20 dans lequel A est l'atome d'hydrogène et B est SR* où R* est un groupe butyle tertiaire ; ou dans lequel B est l'atome d'hydrogène et A est SR* où R* est un groupe butyle tertiaire ; ou dans lequel A est l'atome d'hydrogène et B est SR* où R* est le groupe 3-méthyl-2-buténylе.

22. Procédé selon la revendication 21 dans lequel R** est le groupe éthyle ; ou composé selon la revendication 21 dans lequel R** est l'atome d'hydrogène.

23. Procédé selon l'une des revendications précédentes dans lequel le catalyseur est un complexe de palladium.

24. Procédé selon la revendication 23 dans lequel le complexe de palladium est le $Pd(PQ_3)_2Cl_2$ où Q est un groupe phényle.

25. Procédé selon l'une des revendications précédentes, dans lequel l'acétylure métallique est un sel d'acétylure de zinc.

26. Procédé selon l'une des revendications précédentes dans lequel le composé de formule 2 est un dérivé d'acétylène et la réaction est conduite en présence d'iodure cuivreux et d'un accepteur d'acide tel que la triéthylamine.

27. Procédé de préparation d'un composé de formule (1), ledit composé étant défini dans l'une des revendications 1 à 22, lequel procédé comprend la conversion d'un composé de formule (4) :



Formule 4

où

A, B, R_1, R_2, R_3, Y et E sont tels que définis dans les revendications précédentes 1 à 22 et Z^1 est un précurseur du groupe Z défini plus haut.

28. Procédé de préparation d'une composition pharmaceutique comprenant l'association d'un composé de formule (1) tel que défini dans l'une des revendications 1 à 22 avec un véhicule acceptable sur le plan pharmaceutique

29. Utilisation d'un composé de formule (1) :



où

R_1-R_3 sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, A et B sont indépendamment l'atome d'hydrogène ou un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8}, SR* ou OR* où R* est un groupe alcoyle, cyclo-alcoyle ou alkényle inférieur en C_{1-8} ;
Y est un groupe pyridyle, thiényle, furyle, pyridazinyle, pyrimidinyle, pyrazinyle, thiazolyle ou oxazolyle ;
E est un groupe alkényle inférieur, alkynyle inférieur, cyclo-alcoyle inférieur, ou alcoyle en C_{1-8} à chaîne ramifiée, ou est un groupe caractérisé par la formule $(CH_2)n$ où n est un nombre entier de 0 à 6,
et Z est H, OH, OR', -COOH ou l'un de ses sels, esters ou amides acceptables sur le plan pharmaceutique, $-CH_2OH$ ou l'un de ses dérivés éther ou ester, ou -CHO ou l'un de ses dérivés acétal, ou -COR' ou l'un de ses dérivés cétal, où R' est un groupe alcoyle, cyclo-alcoyle ou alkényle de 1 à 5 atomes de carbone, dans la fabrication d'un médicament destiné au traitement des maladies de la peau

30. Utilisation selon la revendication 29, dans laquelle le composé de formule (1) est un composé de formule (1) tel que défini dans l'une des revendications 1 à 22.